CA2599018C - Methods and systems for operating an aerosol generator - Google Patents
Methods and systems for operating an aerosol generator Download PDFInfo
- Publication number
- CA2599018C CA2599018C CA2599018A CA2599018A CA2599018C CA 2599018 C CA2599018 C CA 2599018C CA 2599018 A CA2599018 A CA 2599018A CA 2599018 A CA2599018 A CA 2599018A CA 2599018 C CA2599018 C CA 2599018C
- Authority
- CA
- Canada
- Prior art keywords
- patient
- ventilator
- aerosol
- inhalation
- aerosolization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 144
- 238000000034 method Methods 0.000 title abstract description 33
- 238000012387 aerosolization Methods 0.000 claims description 71
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 64
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 119
- 238000011282 treatment Methods 0.000 abstract description 13
- 208000019693 Lung disease Diseases 0.000 abstract description 10
- 229960004821 amikacin Drugs 0.000 abstract description 8
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 abstract description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 6
- 239000007864 aqueous solution Substances 0.000 abstract description 6
- 210000002345 respiratory system Anatomy 0.000 abstract description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 4
- 239000012071 phase Substances 0.000 description 83
- 239000007789 gas Substances 0.000 description 44
- 239000006199 nebulizer Substances 0.000 description 38
- 229940079593 drug Drugs 0.000 description 33
- 239000007788 liquid Substances 0.000 description 21
- 230000003434 inspiratory effect Effects 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 230000000241 respiratory effect Effects 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 7
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000003595 mist Substances 0.000 description 7
- 238000009423 ventilation Methods 0.000 description 7
- 229940126575 aminoglycoside Drugs 0.000 description 6
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 6
- 238000012383 pulmonary drug delivery Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 4
- 238000002716 delivery method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 208000030963 borderline personality disease Diseases 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
- 229910001252 Pd alloy Inorganic materials 0.000 description 1
- 229910002669 PdNi Inorganic materials 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- -1 bronchodialators Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229940041024 other aminoglycosides in atc Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A61M16/0833—T- or Y-type connectors, e.g. Y-piece
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A61M16/0841—Joints or connectors for sampling
- A61M16/0858—Pressure sampling ports
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/105—Filters
- A61M16/106—Filters in a path
- A61M16/1065—Filters in a path in the expiratory path
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/208—Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
- A61M2016/0018—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
- A61M2016/0021—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with a proportional output signal, e.g. from a thermistor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3561—Range local, e.g. within room or hospital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3569—Range sublocal, e.g. between console and disposable
Abstract
A method of treating a patient with a pulmonary disease, where the method includes delivering a dose of aerosolized medicament intermittently to a ventilator circuit coupled to the respiratory system of the patient. Also, a method of treating a patient with a pulmonary disease, where the method includes taking the patient off a ventilator, and administering to the patient, a nebulized aerosol comprising from about 100 µg to about 500 mg of a medicament. Additionally, an aerosolized medicament for the treatment of a pulmonary disease, where the medicament includes amikacin mixed with an aqueous solution having an adjusted pH from about 5.5 to about 6.3. The pH is adjusted by adding hydrochloric acid and sodium hydroxide to the aqueous solution.
Description
METHODS AND SYSTEMS FOR OPERATING AN AEROSOL
GENERATOR
FIELD OF THE INVENTION
[0001] The present invention generally relates to systems and methods for the delivery of aerosolized medicaments. More specifically, embodiments of the invention relate to the coupling of aerosol generators with ventilator circuits, permitting an aerosolized medicament to be inhaled directly by a patient.
BACKGROUND OF THE INVENTION
GENERATOR
FIELD OF THE INVENTION
[0001] The present invention generally relates to systems and methods for the delivery of aerosolized medicaments. More specifically, embodiments of the invention relate to the coupling of aerosol generators with ventilator circuits, permitting an aerosolized medicament to be inhaled directly by a patient.
BACKGROUND OF THE INVENTION
[0002] Aerosolized medicaments are used to treat patients suffering from a variety of respiratory ailments. Medicaments can be delivered directly to the lungs by having the patient inhale the aerosol through a tube and/or mouthpiece coupled to the aerosol generator.
By inhaling the aerosolized medicament, the patient can quickly receive a dose of medicament that is concentrated at the treatment site (e.g., the bronchial passages and lungs of the patient). Generally, this is a more effective and efficient method of treating respiratory ailments than first administering a medicament through the patient's circulatory system (e.g., intravenous injection). However, may problems still exist with the delivery of aerosolized medicaments.
By inhaling the aerosolized medicament, the patient can quickly receive a dose of medicament that is concentrated at the treatment site (e.g., the bronchial passages and lungs of the patient). Generally, this is a more effective and efficient method of treating respiratory ailments than first administering a medicament through the patient's circulatory system (e.g., intravenous injection). However, may problems still exist with the delivery of aerosolized medicaments.
[0003] Patients who cannot breathe normally without the aid of a ventilator may only be able to receive aerosolized medicaments through a ventilator circuit. The aerosol generator should therefore be adapted to deliver an aerosol through the ventilator.
Unfortunately, medicament delivery efficiencies for combination nebulizer-ventilator systems are quite low, often dropping below 20%. The ventilator circuits typically force the aerosol to travel through a number of valves, conduits, and filters before reaching the patient's mouth or nose, and all the surfaces and obstacles provide a lot of opportunity for aerosol particles to condense back into the liquid phase.
Unfortunately, medicament delivery efficiencies for combination nebulizer-ventilator systems are quite low, often dropping below 20%. The ventilator circuits typically force the aerosol to travel through a number of valves, conduits, and filters before reaching the patient's mouth or nose, and all the surfaces and obstacles provide a lot of opportunity for aerosol particles to condense back into the liquid phase.
[0004] One problem is that conventional aerosolizing technology is not well suited for incorporation into ventilator circuits. Conventional jet and ultrasonic neublizers normally require 50 to 100 milliseconds to introduce the aerosolized medicament into the circuit. They also tend to produce aerosols with large mean droplet sizes and poor aerodynamic qualities that make the droplets more likely to form condensates on the walls and surfaces of the circuit.
[0005] Delivery efficiencies can also suffer when aerosols are being delivered as the patient exhales into the ventilator. Conventional nebulizers deliver constant flows of aerosol into the ventilator circuit, and the aerosol can linger, or even escape from the circuit when the patient is not inhaling. The lingering aerosol is more likely to condense in the system, and eventually be forced out of the circuit without imparting any benefit to the patient.
[0005] Delivery efficiencies can also suffer when aerosols are being delivered as the patient exhales into the ventilator. Conventional nebulizers deliver constant flows of aerosol into the ventilator circuit, and the aerosol can linger, or even escape from the circuit when the patient is not inhaling. The lingering aerosol is more likely to condense in the system, and eventually be forced out of the circuit without imparting any benefit to the patient.
[0006] The failure of substantial amounts of an aerosolized medicament to reach a patient can be problematic for several reasons. First, the dosage of drug actually inhaled by the patient may be significantly inaccurate because the amount of medication the patient actually receives into the patient's respiratory system may vary with fluctuations of the patient's breathing pattern. Further, a significant amount of drug that is aerosolized may end up being wasted, and certain medications are quite costly, thus health-care costs are escalated.
[0007] Some of the unused medication may also escape into the surrounding atmosphere.
This can end up medicating individuals in proximity to the patient, putting them at risk for adverse health effects. In a hospital environment, these individuals may be health-care providers, who could be exposed to such air pollution over a prolonged period of time, or other patients, who may be in a weakened condition or otherwise sensitive to exposure to unprescribed medications, or an overdose of a medication.
This can end up medicating individuals in proximity to the patient, putting them at risk for adverse health effects. In a hospital environment, these individuals may be health-care providers, who could be exposed to such air pollution over a prolonged period of time, or other patients, who may be in a weakened condition or otherwise sensitive to exposure to unprescribed medications, or an overdose of a medication.
[0008] For these reasons, it's desirable to increase the aerosol delivery efficiencies of nebulizer-ventilator systems. Embodiments of the present invention address these and other problems with conventional systems and methods of treating patients with aerosolized medicaments.
BRIEF SUMMARY OF THE INVENTION
BRIEF SUMMARY OF THE INVENTION
[0009] The present invention provides devices and methods for improving a level of safety to the patient and for providing an increased efficiency of delivery of an aerosol to the patient.
[0010] Embodiments of the invention include a method of treating a patient with a pulmonary disease. The method includes delivering a dose of aerosolized medicament intermittently to a ventilator circuit coupled to the respirator system of the patient.
[0011] Embodiments of the invention also include a method of treating a patient with a pulmonary disease by administering to the patient, through a ventilator circuit, a nebulized aerosol comprising from about 100 jig to about 500 mg of a medicament. The efficiency of the method is such that at least 40% of the nebulized aerosol is delivered to the patient.
[0012] Embodiments of the invention also include a method of treating a patient with a pulmonary disease by taking the patient off a ventilator, and administering to the patient, a nebulized aerosol comprising from about 100 ps to about 500 mg of a medicament.
[0013] Embodiments of the invention still further include methods of treating a pulmonary disease by administering to a patient a medicament comprising an antibiotic dissolved in an aqueous solution comprising sodium chloride that is adjusted to a pH between 5.5 and 6.3.
The medicament is administered by nebulization using a vibratable member with apertures, the member configured to produce 70% or more of aerosol particles with mass mean aerodynamic diameters from about 1 itm to about 7 Am.
The medicament is administered by nebulization using a vibratable member with apertures, the member configured to produce 70% or more of aerosol particles with mass mean aerodynamic diameters from about 1 itm to about 7 Am.
[0014] Embodiments of the invention additionally include a method of treating a patient with a pulmonary disease by administrating an aerosolized medicament to the patient, and administrating, intravenously, a second medicament to the patient that also treats the pulmonary disease.
[0015] Embodiments of the invention yet still further include an aerosolized medicament for the treatment of a pulmonary disease. The medicament includes amikacin mixed with an aqueous solution having an adjusted pH from about 5.5 to about 6.3. The pH is adjusted by adding hydrochloric acid and sodium hydroxide to the aqueous solution.
[0016] Embodiments also include methods of nebulizing a liquid. The method comprises taking one or more breaths and measuring characteristics of the breath.
Another breath is taken and an aerosol generator is operated based on the measured characteristics of the one or more measured breaths.
Another breath is taken and an aerosol generator is operated based on the measured characteristics of the one or more measured breaths.
[0017] Still further embodiments of the invention include methods of providing a nebulizer system comprising a housing, an aerosol generator, a controller coupled to the aerosol generator, and a reservoir in communication with the aerosol generator.
[0018] In still more embodiments, the present invention provides a nebulizer system comprising a housing that defines a passageway that is adapted to deliver an aerosolized liquid to a user. An aerosol generator is positioned to provide an aerosolized liquid into the passageway. A controller having a memory and a plurality of aerosol generator operation programs that control operation of the aerosol generator is coupled to the aerosol generator.
[0019] In yet still more embodiments, the present invention provides a nebulizing element positioned to provide nebulized fluid into a ventilator breathing circuit to provide nebulized fluid to a patient receiving air from a ventilator. It will be appreciated that a nebulizing element may also be referred to herein an aerosolization element, and a ventilator may also be referred to herein as a respirator.
[0020] Embodiments of the invention also provide operation sequences by which aerosol is provided a predetermined points in a breath cycle provided by a ventilator. In one aspect, the present invention provides for an operation sequence in which aerosol production begins at a predetermined point within an inhalation phase, which may also be referred to herein as an inspiratory phase, and stops at a second predetermined point within the same inhalation phase. In another aspect, the present invention provides for an operation sequence, which may be referred to as an operation program, in which aerosol production begins at a predetermined point in an inhalation phase and stops at a point after the inhalation phase has ended, i.e. at a certain point in the exhalation phase. It will be appreciated that the exhalation phase may also be referred to as the expiratory phase, and may encompass the entire period of time during which no inhalation phase is taking place; in other words, the exhalation phase may include not only the actual exhalation of the patient, but also any pause that may occur before or after exhalation. In another aspect, the present invention provides an operation sequence in which aerosolization begins at a predetermined point within the exhalation phase and stops within that exhalation phase, or, alternatively, begins at a predetermined point within an exhalation phase and stops at a predetermined point in the succeeding inhalation phase.
[0021] Embodiments of the invention also provide for selection of a particular operating sequence from a plurality of available operating sequences. Similarly, the present invention provides for modes of operation, which modes may include one or more operating sequences.
[0022] Embodiments additionally provide for algorithms to set forth operation sequences, choice of operation sequences or choice of modes of operation.
[0023] Embodiments also provide for consideration of the identity of a drug to be administered in executing an algorithm, choosing a mode of operation, or selecting or running an operation sequence.
[0024] Embodiments of the invention also provide for nebulization of particular drug groups or drugs, such as, for example, antibodies, such as IgG or antibiotics, such as aminoglycosides, such as amikacin.
[0025] Embodiments still further provide for a nebulized droplet ejection device for use with a ventilator, wherein the device produces droplets by a vibratory apertured element during a selected interval of a breathing cycle.
[0026] Embodiments additionally provide for apparatus and methods for varying the particle size distribution of a nebulized mist by varying the aperture exit diameter of an apertured vibratory aerosolization element.
[0027] Additional embodiments and features are set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the specification or may be learned by the practice of the invention. The features and advantages of the invention may be realized and attained by means of the instrumentalities, combinations, and methods described in the specification.
BRIEF DESCRlPTION OF THE DRAWINGS
BRIEF DESCRlPTION OF THE DRAWINGS
[0028] Figure 1A illustrates components of a pulmonary drug delivery system according to embodiments of the invention;
[0029] Figure 1B shows an embodiment of a junction device that can be used in a pulmonary drug delivery system according to embodiments of the invention;
[0030] Figure 2 shows an on-ventilator configuration of a pulmonary drug delivery system according to embodiments of the invention;
[0031] Figure 3 is a schematic perspective view of a nebulizer incorporated into a ventilator breathing circuit in accordance with the present invention;
[0032] Figures 4A-D show off-ventilator configurations of pulmonary drug delivery systems according to embodiments of the invention;
[0033] Figure 5 shows a nebulizer coupled to T-piece adaptor for a ventilator circuit according to embodiments of the invention;
[0034] Figure 6 shows an exploded view of a nebulizer according to embodiments of the invention;
[0035] Figure 7 is a schematic cross-sectional representation of an aerosol generator in accordance with the present invention;
[0036] Figure 8 is a schematic cutaway cross-section detail of the aerosol generator represented in Figure 6A;
[0037] Figure 9 shows an exploded view of a nebulizer coupled to a filter according to embodiments of the invention;
[0038] Figures 10A-B show the flow of gases and medicaments through a nebulizer-filter system according to embodiments of the invention;
[0039] Figures 11A-B show the flow of gases through a chamber and filter according to embodiments of the invention;
[0040] Figures 12A-C show graphs of various modes of aerosolization over the course of breathing cycles;
[0041] Figure 13 illustrates a simplified method of the present invention;
[0042] Figure 14 is a schematic representation of algorithms of operating sequences in accordance with the present invention;
[0043] Figure 15 is an alternative schematic representation of the algorithms of operating sequences of Figure 14;
[0044] Figure 16 is a further schematic representation of algorithms of operating sequences shown in Figure 15, and in accordance with the present invention; and [0045] Figure 17 is a schematic representation of an algorithm by which an operating sequence may be chosen base on the combination of a plurality of independent sets of information.
DETAILED DESCRIPTION OF THE INVENTION
Overview [0046] As noted above, conventional nebulizer-ventilator systems have low medicament delivery efficiency (e.g., less than 20%). Embodiments of the invention include methods and systems for increasing delivery efficiencies to at least 40%, and in many instances to about 70% or more. The increased efficiency for delivering the aerosolized medicament may be attributable, in part, to one or more features that may be implemented in embodiments of the invention. These features include synchronizing the generation of aerosol with an inspiratory phase of the ventilator cycle (e.g., phasic delivery). The features may also include supplying air (e.g., an "air chaser") following aerosol generation, which can clear the endotracheal tube and reduce the amount of medicament exhaled by the patient. Features may further include connecting the aerosol generating unit directly to the hub of the endotrcheal tube that is connected to the patient. Still other features include generating aerosolized medicament with smaller particle sizes (e.g., about 1 to 5 Am average diameter). Additional features may also include storing the medicament in a conical shaped reservoir to minimize the residual medicament volume.
DETAILED DESCRIPTION OF THE INVENTION
Overview [0046] As noted above, conventional nebulizer-ventilator systems have low medicament delivery efficiency (e.g., less than 20%). Embodiments of the invention include methods and systems for increasing delivery efficiencies to at least 40%, and in many instances to about 70% or more. The increased efficiency for delivering the aerosolized medicament may be attributable, in part, to one or more features that may be implemented in embodiments of the invention. These features include synchronizing the generation of aerosol with an inspiratory phase of the ventilator cycle (e.g., phasic delivery). The features may also include supplying air (e.g., an "air chaser") following aerosol generation, which can clear the endotracheal tube and reduce the amount of medicament exhaled by the patient. Features may further include connecting the aerosol generating unit directly to the hub of the endotrcheal tube that is connected to the patient. Still other features include generating aerosolized medicament with smaller particle sizes (e.g., about 1 to 5 Am average diameter). Additional features may also include storing the medicament in a conical shaped reservoir to minimize the residual medicament volume.
[0047] Embodiments of the systems are configurable to administer aerosolized medicament to a patient both on-ventilator and off-ventilator. On-ventilator treatment methods include administering the nebulized aerosol through a ventilator circuit to the patient. Aerosol doses, containing about 1 to about 500 mg of a medicament, may be delivered through the ventilator circuit in a phasic or non-phasic manner. Off-ventilator treatment methods may include taking the patient off the ventilator before administering the nebulized aerosol. Once the treatment session is completed the patient may be put back on the ventilator, or may breathe on his or her own without assistance.
[0048] Embodiments of the invention provide treatments for a variety of ailments using a variety of aerosolizable medicaments. The ailments may include pulmonary ailments such as ventilator-associated pneumonia, hospital-acquired pneumonia, cystic fibrosis, mycobacterial infection, bronchitis, staph infection, fungal infections, viral infections, protozal infections, and acute exacerbation of Chronic Obstructive Pulmonary Disease, among others.
The aerosolizable medicaments used to treat the ailments may include antibiotics, anti-oxidants, bronchodialators, corticosteroids, leukotrienes, protease inhibitors, and surfactants, among other medicaments.
Exemplary Pulmonary Drug Delivery Systems [0049] Fig. 1A shows an embodiment of a pulmonary drug delivery system ("PDDS") 100 according to the invention. The PDDS 100 may include a nebulizer 102 (also called an aerosolizer), which aerosolizes a liquid medicament stored in reservoir 104.
The aerosol exiting nebulizer 102 may first enter the T-adaptor 106 that couples the nebulizer 102 to the ventilator circuit. The T-adaptor 106 is also coupled to the circuit wye 108 that has branching ventilator limbs 110 and 112.
The aerosolizable medicaments used to treat the ailments may include antibiotics, anti-oxidants, bronchodialators, corticosteroids, leukotrienes, protease inhibitors, and surfactants, among other medicaments.
Exemplary Pulmonary Drug Delivery Systems [0049] Fig. 1A shows an embodiment of a pulmonary drug delivery system ("PDDS") 100 according to the invention. The PDDS 100 may include a nebulizer 102 (also called an aerosolizer), which aerosolizes a liquid medicament stored in reservoir 104.
The aerosol exiting nebulizer 102 may first enter the T-adaptor 106 that couples the nebulizer 102 to the ventilator circuit. The T-adaptor 106 is also coupled to the circuit wye 108 that has branching ventilator limbs 110 and 112.
[0050] Coupled to one of the ventilator limbs 110 or 112 may be an air pressure feedback unit 114, which equalizes the pressure in the limb with the air pressure feedback tubing 116 connected to the control module 118. In the embodiment shown, feedback unit 114 has a female connection end (e.g., an ISO 22mm female fitting) operable to receive ventilator limb 112, and a male connection end (e.g., an ISO 22mm male fitting) facing opposite, and operable to be inserted into the ventilator. The feedback unit may also be operable to receive a filter 115 that can trap particulates and bacteria attempting to travel between the ventilator circuit and tubing 116.
[0051] The control module 118 may monitor the pressure in the ventilator limb via tubing 116, and use the information to control the nebulizer 102 through system cable 120. In other embodiments (not shown) the control module 118 may control aerosol generation by transmitting wireless signals to a wireless control module on the nebulizer 102.
[0052] During the inhalation phase of the patient's breathing cycle, aerosolized medicament entering T-adaptor 106 may be mixed with the respiratory gases from the inspiratory ventilator limb 112 flowing to the patient's nose and/or lungs. In the embodiment shown, the aerosol and respiratory gases flow through nose piece 122 and into the nasal passages of the patient's respiratory tract.
[0053] Other embodiments of the circuit wye 108 shown in Fig. 1A are also contemplated in embodiments of the invention. For example, an alternate embodiment of the wye 108 is illustrated in Fig. 1B, which shows junction device 135, which may be configured downstream from nebulizer 102. In the downstream configuration, gas flow 150 containing aerosolized medicament enters the junction device 135 at first end 143 and exits at second end 144 of the respiratory circuit. The junction device 135 includes a tubular main body member 141 having a straight longitudinal lumen 142 connecting the opening in a first end 143 attachable to inspiratory tube 112 and an opening in a second end 144 attachable to a patient interface, such as nose piece 122. Junction device 135 may further comprise a tubular branch member 145 having a lumen 146 that communicates with lumen 142 at intermediate opening 147. Gas flow 150 contains aerosol particles of medicament emitted by nebulizer 102 that pass from inspiratory tube 112 into lumen 142 through the opening in first end 143.
[0054] In contrast to a "Y"-shaped junction device, junction device 135 provides for gas flow 150 (containing aerosolized medicament) to follow a straight unobstructed path through the respiratory circuit without any portion being diverted into branch member 145. In other words, there is virtually no change in the angle of the path of gas flow 150.
As a result, the full amount of aerosol particles of medicament contained in gas flow 150 is efficiently delivered through the respiratory circuit to the patient. Upon expiratory effort by the patient, expiratory gas flow 152 follows a path through lumen 142 to lumen 146 of branch member 145 and through expiratory tube 110 back to the ventilator (not shown).
As a result, the full amount of aerosol particles of medicament contained in gas flow 150 is efficiently delivered through the respiratory circuit to the patient. Upon expiratory effort by the patient, expiratory gas flow 152 follows a path through lumen 142 to lumen 146 of branch member 145 and through expiratory tube 110 back to the ventilator (not shown).
[0055] Fig. 2 shows another embodiment of a PDDS 200, where nose piece 122 has been replaced by ET tube 222. In this embodiment, during inhalation the aerosolized medicament generated by nebulizer 202 is carried by the flow of respiratory gases through the ET tube 222 and into the patient's bronchial passages and lungs.
[0056] Referring to Fig. 3, a nebulizer 85, which may have a top portion 93 through which liquid may be provided may be incorporated into a ventilator breathing circuit of a ventilated patient. The breathing circuit may comprise a "Y" connector 88, which may in turn have an inlet portion 89, an endotracheal tube portion 90 and an outlet portion 91.
The inlet portion 89 carries air provided from the ventilator 92 toward the patient. The endotracheal tube portion 90 of the Y connector 88 carries the incoming air to the patient's respiratory tract; this direction is represented by arrow "a". The endotracheal tube portion 90 also carries the patient's exhalation to the outlet portion 91 of the Y connector 88, and the outlet portion may lead to an exhaust, represented by arrow "b", to remove the patient's exhalation from the system. The nebulizer 85 of the present invention aerosolization element generates an aerosol cloud 94 that remains substantially within the inlet portion 89 of the Y connector 88 when there is no inspiratory air flowing through the inlet portion, by virtue of the aerosolization element, as described above, producing a low velocity mist. In this manner, aerosol that is generated when there is no inhalation air being provided will not be carried out through the outlet portion 91 of the Y connector and lost to the ambient environment.
Accordingly, a dose of aerosolized medication may be preloaded, i.e., produced and placed substantially within the inlet portion 89 prior to an inhalation phase being sent by the ventilator 92. In this manner, such medication can be swept into a patient's respiratory system at the very start of the inhalation cycle. This may be of particular benefit in the case of neonatal patients and in other instances in which only the initial blast of inhalation phase will reach the target portion of the respiratory system. In alternate embodiments, the ventilator may generate a continuous bias flow of gas through the ventilator circuit. The bias flow may push some of the aerosolized medicament through the outlet portion 91, but there is still an overall benefit from having the aerosolized medicament preloaded through the ventilator circuit.
The inlet portion 89 carries air provided from the ventilator 92 toward the patient. The endotracheal tube portion 90 of the Y connector 88 carries the incoming air to the patient's respiratory tract; this direction is represented by arrow "a". The endotracheal tube portion 90 also carries the patient's exhalation to the outlet portion 91 of the Y connector 88, and the outlet portion may lead to an exhaust, represented by arrow "b", to remove the patient's exhalation from the system. The nebulizer 85 of the present invention aerosolization element generates an aerosol cloud 94 that remains substantially within the inlet portion 89 of the Y connector 88 when there is no inspiratory air flowing through the inlet portion, by virtue of the aerosolization element, as described above, producing a low velocity mist. In this manner, aerosol that is generated when there is no inhalation air being provided will not be carried out through the outlet portion 91 of the Y connector and lost to the ambient environment.
Accordingly, a dose of aerosolized medication may be preloaded, i.e., produced and placed substantially within the inlet portion 89 prior to an inhalation phase being sent by the ventilator 92. In this manner, such medication can be swept into a patient's respiratory system at the very start of the inhalation cycle. This may be of particular benefit in the case of neonatal patients and in other instances in which only the initial blast of inhalation phase will reach the target portion of the respiratory system. In alternate embodiments, the ventilator may generate a continuous bias flow of gas through the ventilator circuit. The bias flow may push some of the aerosolized medicament through the outlet portion 91, but there is still an overall benefit from having the aerosolized medicament preloaded through the ventilator circuit.
[0057] PDDS systems like the ones described above in Figs. 1-3 may include equipment for phasic delivery of aerosolized medicaments. This equipment may include breathing characteristics sensors, which can monitor the breathing characteristics of a patient using the PDDS. The sensors can send breathing characteristic information to the PDDS
controller to allow the controller to select an appropriate delivery cycle of the aerosolized liquid to the patient. Typically, breathing characteristic sensors can be used to measure a breathing pattern of the patient, the peak flow, breathing rate, exhalation parameters, regularity of breathing, and the like. Such measured breathing characteristics data be delivered to controller by analog or digital signals, and run through a software algorithm to determine an appropriate sequence of delivery relative to the measured breathing cycle to the patient.
controller to allow the controller to select an appropriate delivery cycle of the aerosolized liquid to the patient. Typically, breathing characteristic sensors can be used to measure a breathing pattern of the patient, the peak flow, breathing rate, exhalation parameters, regularity of breathing, and the like. Such measured breathing characteristics data be delivered to controller by analog or digital signals, and run through a software algorithm to determine an appropriate sequence of delivery relative to the measured breathing cycle to the patient.
[0058] For example, one exemplary breathing characteristic that may be sensed by a sensor is the cycle of a ventilator providing air to a patient; for example, the start of an inhalation cycle generated by the ventilator. The sensor may also sense other parameters, for example, it may be an acoustic sensor that is activated through passing the respiratory flow of the patient through an acoustic chamber so as to produce an acoustic tone, which is proportional to the inspiratory flow rate. The frequency of the acoustic tone indicates the inspiratory flow rate at any instant of the breathing cycle. The acoustic signal can be detected by the controller such that integration of the flow rate with time produces the tidal volume. Both the flow rate and the tidal volume can then be used by the controller to determine when the aerosol generator generates the droplets and at what mass flow rate such that maximum deposition of droplets is obtained. Further, the acoustic tone may be recorded to produce a record of the breathing pattern of the patient which may be stored in the microprocessor.
This information can be later used to synchronize the ejection of droplets for the same patient. Such information may also be later employed for other diagnostic purposes. A more complete description of such sensors are described in commonly owned, U.S.
Patent 5,758,637, which was previously incorporated by reference.
This information can be later used to synchronize the ejection of droplets for the same patient. Such information may also be later employed for other diagnostic purposes. A more complete description of such sensors are described in commonly owned, U.S.
Patent 5,758,637, which was previously incorporated by reference.
[0059] In some embodiments, the sensors can be used to monitor the breathing characteristics of the patient throughout the delivery regime so as to ensure that the aerosol is efficiently delivered throughout the aerosolization procedure. In such embodiments, the controller can adjust the aerosol delivery based on any measured change in the breathing pattern of the patient during the aerosolization. With this monitoring and adjustment predetermined times for the beginning and ending of aerosolization can be reset based on the actual breathing of the patent. In other embodiments, however, the breathing sensor can be used to determine the breathing cycle of a tidal breath and to choose the appropriate pre-programmed delivery cycle that is stored in the memory of the controller. In other embodiments, the controller may be configured to provide aerosol based on the time. For example, the controller may be configured to start aerosol production at the beginning of an inhalation phase of a breathing cycle and stop at a point at which a predetermined percentage of the inhalation has taken place. Alternatively, the controller may be configured to start aerosolization at a first point at which a first predetermined percentage has taken place, and stop aerosolization at a second point at which a second predetermined percentage of that inhalation has taken place. Alternatively, aerosol may begin during an inhalation phase and end during the subsequent exhalation phase. Alternatively, the controller may be configured to begin aerosol production at a certain point during exhalation and stop during that exhalation or during the subsequent inhalation. Thus, embodiments of the PDDS
may include a nebulizer having an aerosol generator and a controller configured to have the controller begin aerosolization during exhalation and stop during that exhalation or in the subsequent inhalation. In still other embodiments, the controller may be configured to begin aerosol production at a start point in the breathing cycle, and continue to generate aerosol for a set period of time regardless of how a patient's breathing cycle varies. At the end of the time period, aerosol generation stops until the next start point is in the breathing cycle. In further embodiments, the controller may be configured to start and stop aerosol production for preprogrammed periods of time that are independent of the patient's breathing cycle.
may include a nebulizer having an aerosol generator and a controller configured to have the controller begin aerosolization during exhalation and stop during that exhalation or in the subsequent inhalation. In still other embodiments, the controller may be configured to begin aerosol production at a start point in the breathing cycle, and continue to generate aerosol for a set period of time regardless of how a patient's breathing cycle varies. At the end of the time period, aerosol generation stops until the next start point is in the breathing cycle. In further embodiments, the controller may be configured to start and stop aerosol production for preprogrammed periods of time that are independent of the patient's breathing cycle.
[0060] The controller may be operable to allow for a choice of modes of operation, for example, a mode in which aerosolization begins once a certain breath characteristic is detected, such as a sufficient level of inhalation, and ends when there is no longer a sufficient level; another mode in which aerosolization begins once a certain breath characteristic is detected, such as a sufficient level of inhalation, and ends at a predetermined time within the inhalation cycle, such as for example, before the level of inhalation falls below that required for operation of an aerosolization element, or, alternatively, at any other point within the inhalation cycle, such as after the inhalation phase of the cycle before exhalation has begun, or after exhalation has begun.
[0061] The level of inhalation may be sensed by a pressure sensor. Such a transducer may monitor a drop in air pressure or a rise in air pressure within a chamber that is in fluid communication with the ventilator circuit. In this manner, a pressure drop may be sensed by a patient inhaling through the circuit, for example, in an instance in which the ventilator provides assisted ventilation initiated by a patient's commencement of an inhalation.
Similarly, a pressure rise may be sensed in an instance in which the ventilator pushes inhalation air to the patient without the patient initiating a breath. Another mode in which the controller may be operable is a mode in which the on / off operation of the aerosol generator is triggered by time, which may be ascertained from an internal clock device, such as a clock built into a microprocessor, or from an external source. Another mode in which the controller may be operable is in which the on / off operation of the aerosol is triggered by the controller receiving an external signal, such as a signal from a ventilator, which can correspond to the point in the ventilator's cycle of that is the start of an inhalation phase in which the ventilator begins to push inspiratory air into the ventilator circuit. The controller may be operable between such modes, including a mode in which the aerosolization begins at a predetermined time in the breathing cycle and ends at a predetermined time in the breathing cycle. The first and second predetermined times in the third mode may be during inhalation.
Alternatively, the first and second predetermined times may be during exhalation, or at the first predetermined time may be during exhalation and the second predetermined time may be during subsequent inhalation. These times may correspond to certain percentages of the inhalation phase taking place, or any other points of reference within a breathing cycle.
Similarly, a pressure rise may be sensed in an instance in which the ventilator pushes inhalation air to the patient without the patient initiating a breath. Another mode in which the controller may be operable is a mode in which the on / off operation of the aerosol generator is triggered by time, which may be ascertained from an internal clock device, such as a clock built into a microprocessor, or from an external source. Another mode in which the controller may be operable is in which the on / off operation of the aerosol is triggered by the controller receiving an external signal, such as a signal from a ventilator, which can correspond to the point in the ventilator's cycle of that is the start of an inhalation phase in which the ventilator begins to push inspiratory air into the ventilator circuit. The controller may be operable between such modes, including a mode in which the aerosolization begins at a predetermined time in the breathing cycle and ends at a predetermined time in the breathing cycle. The first and second predetermined times in the third mode may be during inhalation.
Alternatively, the first and second predetermined times may be during exhalation, or at the first predetermined time may be during exhalation and the second predetermined time may be during subsequent inhalation. These times may correspond to certain percentages of the inhalation phase taking place, or any other points of reference within a breathing cycle.
[0062] Alternatively, the first predetermined time and the second predetermined time may be designated as any point within a single breathing cycle, or alternatively, the first predetermined point may be at any point within one breathing cycle and the second predetermined point may be at any point in a subsequent breathing cycle. The controller may make the determination of when to begin, and operate to begin aerosolization, and may make the determination of when to stop aerosolization to stop, and cause aerosolization to stop.
The controller may make such determinations and take such actions based on accessing stored algorithms. The controller may receive a signal from the ventilator that establishes a reference point, nonetheless, the controller, by making the determinations an taking the actions based on stored algorithms, and/or information obtained as to the identity of a drug to be administered, may cause aerosol production to begin and/or end independent of the instantaneous position of the ventilator with respect to the ventilator cycle.
The controller may make such determinations and take such actions based on accessing stored algorithms. The controller may receive a signal from the ventilator that establishes a reference point, nonetheless, the controller, by making the determinations an taking the actions based on stored algorithms, and/or information obtained as to the identity of a drug to be administered, may cause aerosol production to begin and/or end independent of the instantaneous position of the ventilator with respect to the ventilator cycle.
[0063] Embodiments also include a controller operable to allow for a single mode of operation, where the single mode of operation may be any mode, including but not limited to the modes described above. For example, a mode in which aerosolization begins once a certain breath characteristic is detected, such as a sufficient level of inhalation, and ends when there is no longer a sufficient level. Similarly, the controller may operable in a mode in which aerosolization begins once a certain breath characteristic is detected, such as a sufficient level of inhalation, and ends at a predetermined time within the inhalation before there is no longer a sufficient level or an aerosolization element.
[0064] Alternatively, the mode may be a mode in which the aerosolization is commenced based on a signal from the ventilator indicating the attainment of a certain point within the ventilation output cycle or the inhalation cycle of the patient. (The ventilation output cycle of the ventilator may coincide with the inhalation cycle of the patient, such that the ventilation output phase of the ventilator output cycle and the inhalation phase of the inspiratory cycle of the patient occur substantially simultaneously. Such may be the case where a patient is completely passive and the only inhalation that occurs is by generation of air from the ventilator during the output phase of the ventilator cycle.). Such point may be during the output phase of the output cycle of the ventilator or during the inhalation phase of the inhalation cycle of the patient. The predetermined point can be chosen to coincide with a certain level of output from the ventilator or at a certain point in time during the ventilator output cycle. Such a predetermined point may be a specific point within the output phase of the ventilator cycle, or, a specific point within the non-output phase of the ventilator cycle, based, for example, on the timing of the previous or succeeding output phase of the ventilator. In another aspect, the present invention provides for a ventilator along with the aerosol generator and controller. In an aspect of the invention, a predetermined time may be based on the timing of a ventilator supplying air to a user. In this manner, the controller may be set to work off of the timing of the ventilator in one mode, while working off the patient's inspiratory effort in another mode, or mode that allows for a combination of the patient's inspiratory effort and the timing of the ventilator, for example, where the ventilator is set to assist the patient by supplying air upon the patient's effort or where the patient has not made a sufficient effort within a predetermined period of time.
Exemplary Off-Ventilator Configurations [0065] Referring now to Figs. 4A-D embodiments of off-ventilator configurations of a PDDS are shown. In Fig. 4A, the off-ventilator PDDS 400 includes an endpiece 402 that is coupled to a nebulizer 404 and wye 406. The nebulizer 404 may include reservoir 408, which supplies the liquid medicament that is aerosolized into connector 410.
The connector [0066] The off-ventilator PDDS 400 may also include a second wye limb 420, which includes a filter 422 and one-way valve 424, through which gases may pass during an [0067] Fig. 4B shows another embodiment of an off-ventilator PDDS 450, where the [0068] Fig. 4C shows still another embodiment of an off-ventilator PDDS 470, where the endpiece is replaced by a facemask 472, operable to sealingly encompass the nose and mouth of a patient. The facemask 472 may have a coupling end, which can resiliently couple the [0069] Fig. 4D shows yet another embodiment of an off-ventilator PDDS 490, where the endpiece, T-piece, and wye form a single continuous piece 492. A gas inlet may be contiguously formed in the piece 492 to connect a gas source, such as oxygen.
A nebulizer inlet to removably receive a nebulizer may also be formed in piece 492. In addition, a filter 496 and one-Way valve 498 may be coupled to a branched end of the piece 492.
Another branched end of piece 492 may also be coupled to a one-way valve 499, operable to prevent gases from back flowing into a pump or other pressurized gas source (not shown) coupled to the branched end.
Exemplary Off-Ventilator Configurations [0065] Referring now to Figs. 4A-D embodiments of off-ventilator configurations of a PDDS are shown. In Fig. 4A, the off-ventilator PDDS 400 includes an endpiece 402 that is coupled to a nebulizer 404 and wye 406. The nebulizer 404 may include reservoir 408, which supplies the liquid medicament that is aerosolized into connector 410.
The connector [0066] The off-ventilator PDDS 400 may also include a second wye limb 420, which includes a filter 422 and one-way valve 424, through which gases may pass during an [0067] Fig. 4B shows another embodiment of an off-ventilator PDDS 450, where the [0068] Fig. 4C shows still another embodiment of an off-ventilator PDDS 470, where the endpiece is replaced by a facemask 472, operable to sealingly encompass the nose and mouth of a patient. The facemask 472 may have a coupling end, which can resiliently couple the [0069] Fig. 4D shows yet another embodiment of an off-ventilator PDDS 490, where the endpiece, T-piece, and wye form a single continuous piece 492. A gas inlet may be contiguously formed in the piece 492 to connect a gas source, such as oxygen.
A nebulizer inlet to removably receive a nebulizer may also be formed in piece 492. In addition, a filter 496 and one-Way valve 498 may be coupled to a branched end of the piece 492.
Another branched end of piece 492 may also be coupled to a one-way valve 499, operable to prevent gases from back flowing into a pump or other pressurized gas source (not shown) coupled to the branched end.
[0070] The on and off-ventilator configurations of the PDDS allow continuity of treatment as the patient switches between on-vent and off-vent treatment configurations.
In both configurations, a patient is able to receive the same aerosolized medicament at the same dosage level, providing a continuity of treatment as the patient transitions from on-ventilator care to off-ventilator care. This can be particularly useful for extended treatment regimens, when the patient receives the aerosolized medicament for several days or weeks.
Exemplary Nebulizers [0071] In regard to the nebulizers (i.e., aerosol generators), they may be of the type, for example, where a vibratable member is vibrated at ultrasonic frequencies to produce liquid droplets. Some specific, non-limiting examples of technologies for producing fine liquid droplets is by supplying liquid to an aperture plate having a plurality of tapered apertures and vibrating the aperture plate to eject liquid droplets through the apertures.
Such techniques are described generally in U.S. Patent Nos. 5,164,740; 5,938,117; 5,586,550;
5,758,637, 6,014,970, and 6,085,740.
However, it should be appreciated that the present invention is not limited for use only with such devices.
In both configurations, a patient is able to receive the same aerosolized medicament at the same dosage level, providing a continuity of treatment as the patient transitions from on-ventilator care to off-ventilator care. This can be particularly useful for extended treatment regimens, when the patient receives the aerosolized medicament for several days or weeks.
Exemplary Nebulizers [0071] In regard to the nebulizers (i.e., aerosol generators), they may be of the type, for example, where a vibratable member is vibrated at ultrasonic frequencies to produce liquid droplets. Some specific, non-limiting examples of technologies for producing fine liquid droplets is by supplying liquid to an aperture plate having a plurality of tapered apertures and vibrating the aperture plate to eject liquid droplets through the apertures.
Such techniques are described generally in U.S. Patent Nos. 5,164,740; 5,938,117; 5,586,550;
5,758,637, 6,014,970, and 6,085,740.
However, it should be appreciated that the present invention is not limited for use only with such devices.
[0072] Referring now to Fig. 5, a nebulizer 502 coupled to a T-piece 504 is shown. The nebulizer 502 may include a reservoir 506 that is orientated at a non-perpendicular angle to the T-piece 504. For example, the reservoir 506 may be formed at an angle between about 100 and about 750 with respect to an axis that is collinear with the base conduit of the T-piece 504. The reservoir 506 may have a cap 508 that can sealingly engage an opening in the reservoir 506 to contain a liquid medicament 509 in the reservoir body 510.
The cap 508 and top of the reservoir 506 may have conjugate threads or grooves that can be sealingly engaged to close the reservoir. Alternatively, the cap 508 may be made from an elastomeric material that can be elastomerically sealed or snapped into place around the opening in the reservoir 506. The reservoir 506 may be refilled by removing cap 508, adding liquid medicament to the reservoir body 510, and resealing the cap 508 on the reservoir 506. In the embodiment shown, about 4 mL of medicament may be stored in the reservoir body 510. In additional embodiments, the volume of medicament stored may range from about 1 mL to about 10mL, and larger reservoirs may hold 10 mL or more of a medicament.
The cap 508 and top of the reservoir 506 may have conjugate threads or grooves that can be sealingly engaged to close the reservoir. Alternatively, the cap 508 may be made from an elastomeric material that can be elastomerically sealed or snapped into place around the opening in the reservoir 506. The reservoir 506 may be refilled by removing cap 508, adding liquid medicament to the reservoir body 510, and resealing the cap 508 on the reservoir 506. In the embodiment shown, about 4 mL of medicament may be stored in the reservoir body 510. In additional embodiments, the volume of medicament stored may range from about 1 mL to about 10mL, and larger reservoirs may hold 10 mL or more of a medicament.
[0073] The nebulizer 502 may also include a power inlet 512 that can receive a plug 514 that supplies electric power to the nebulizer. Alternatively, the power inlet 512 may be replaced or supplemented by a power cord that terminates with a plug that can be plugged into a power source (not shown). The inlet 512 may also receive an electronic control signal that can control the timing and frequency which the nebulizer aerosolizes medicament from the reservoir 506.
[0074] Fig. 6 shows an exploded view of a nebulizer 600 decoupled from the T-piece (not shown), according to an embodiment of the invention. An opening 602 in the nebulizer 600 that couples to the T-piece, or some other inlet in the PDDS, may include an aerosolization element 604 secured within the opening 602 by retaining element 606. In operation, medicament from the reservoir 608 passes through outlet 610 and is aerosolized by the aerosolization element 604. The aerosolized medicament may then drift or flow past retaining element 606 and into the PDDS. Alternative embodiments, not shown, may have the aerosolization element 604 permanently affixed, or integral to, the opening 602, and retaining element 606 may be absent.
[0075] The aerosolization element 604 may have a vibratable member that moves with respect to an aperture plate to aerosolized the liquid medicament. By utilizing an aerosol generator that produces aerosol by the electric powering of the vibratable member that causes the aperture plate to eject liquid at one face thereof, through its apertures, as a mist from the other face thereof, as generally described above (and as described generally in U.S. Patent Nos. 5,164,740; 5,938,117; 5,586,550; 5,758,637, 6,085,740; and 6,235,177), the starting and stopping of aerosol generation may be controlled on the level of accuracy of microseconds or milliseconds, thus providing accurate dosing. The timing of aerosol generation can be done based solely on a predetermined timing within a breathing cycle, on timing in conjunction with the length of a prior breath or portions thereof, on other breathing characteristics, on particular medication being administered, or a combination of any of these criteria.
[0076] The aerosolization element may be constructed of a variety of materials, comprising metals, which may be electroformed to create apertures as the element is formed, as described, for example, in U.S. patent No. 6,235,177 assigned to the present assignee.
Palladium is believed to be of particular usefulness in producing an electroformed, multi-apertured aerosolization element, as well as in operation thereof to aerosolize liquids. Other metals that can be used are palladium alloys, such as PdNi, with, for example, 80 percent palladium and 20% nickel. Other metals and materials may be used without departing from the present invention.
Palladium is believed to be of particular usefulness in producing an electroformed, multi-apertured aerosolization element, as well as in operation thereof to aerosolize liquids. Other metals that can be used are palladium alloys, such as PdNi, with, for example, 80 percent palladium and 20% nickel. Other metals and materials may be used without departing from the present invention.
[0077] Referring now to Figs. 7 and 8, an aerosolization element 70 may be configured to have a curvature, as in a dome shape, which may be spherical, parabolic or any other curvature. The aerosolization element may be formed to have a dome portion 73 over its majority, and this may be concentric with the center of the aerosolization element, thus leaving a portion of the aerosolization element that is a substantially planar peripheral ring portion 75. The aerosolization element has a first face 71, a second face 72.
As shown in Fig. 8, the aerosolization element may also have a plurality of apertures 74 therethrough. The first face 71 may comprise the concave side of the dome portion 72 and the second face 72 may comprise the convex side of the dome portion 72 of the aerosolization element 70. The apertures may be tapered to have a narrow portion 76 at the first face 71 and a wide portion 78 at the second face 72 of the aerosolization element 70. Typically, a liquid will be placed at the first face of the aerosolization element, where it can be drawn into the narrow portion 76 of the apertures 74 and emitted as an aerosolized mist or cloud 79 from the wide portion =
78 of the apertures 74 at the second face 72 of the aerosolization element 70.
[0078] The aerosolization element may be mounted on an aerosol actuator 80, which defines an aperture 81 therethrough. This may be done in such a manner that the dome portion of the aerosolization element protrudes through the aperture 81 of the aerosol actuator 80 and the substantially planar peripheral ring portion 74, on the second face 72 of the aerosolization element 70 abuts a first face 82 of the aerosol actuator 80. A
vibratory element 84 may be provided, and may be mounted on the first face 82 of the aerosol actuator 80, or alternatively may be mounted on an opposing second face 83 of the aerosol actuator 80. The aerosolization element may be vibrated in such a manner as to draw liquid through the apertures 74 of the aerosolization element 70 from the first face to the second face, where the liquid is expelled from the apertures as a nebulized mist. The aerosolization element may be vibrated by a vibratory element 84, which may be a piezoelectric element. The vibratory element may be mounted to the aerosol actuator, such that vibration of the vibratory element may be mechanically transferred through the aerosol actuator to the aerosolization element.
The vibratory element may be annular, and may surround the aperture of the aerosol actuator, for example, in a coaxial arrangement.
As shown in Fig. 8, the aerosolization element may also have a plurality of apertures 74 therethrough. The first face 71 may comprise the concave side of the dome portion 72 and the second face 72 may comprise the convex side of the dome portion 72 of the aerosolization element 70. The apertures may be tapered to have a narrow portion 76 at the first face 71 and a wide portion 78 at the second face 72 of the aerosolization element 70. Typically, a liquid will be placed at the first face of the aerosolization element, where it can be drawn into the narrow portion 76 of the apertures 74 and emitted as an aerosolized mist or cloud 79 from the wide portion =
78 of the apertures 74 at the second face 72 of the aerosolization element 70.
[0078] The aerosolization element may be mounted on an aerosol actuator 80, which defines an aperture 81 therethrough. This may be done in such a manner that the dome portion of the aerosolization element protrudes through the aperture 81 of the aerosol actuator 80 and the substantially planar peripheral ring portion 74, on the second face 72 of the aerosolization element 70 abuts a first face 82 of the aerosol actuator 80. A
vibratory element 84 may be provided, and may be mounted on the first face 82 of the aerosol actuator 80, or alternatively may be mounted on an opposing second face 83 of the aerosol actuator 80. The aerosolization element may be vibrated in such a manner as to draw liquid through the apertures 74 of the aerosolization element 70 from the first face to the second face, where the liquid is expelled from the apertures as a nebulized mist. The aerosolization element may be vibrated by a vibratory element 84, which may be a piezoelectric element. The vibratory element may be mounted to the aerosol actuator, such that vibration of the vibratory element may be mechanically transferred through the aerosol actuator to the aerosolization element.
The vibratory element may be annular, and may surround the aperture of the aerosol actuator, for example, in a coaxial arrangement.
[0079] Embodiments of the invention include the aerosolization element, or the aerosol generator, comprising the aerosolization element 70, the aerosol actuator 80 and the vibratory element 86 may be replaced with a respective assembly that has apertures of a different size, such as a different exit diameter, to produce a mist having a different aerosol particle size. A
circuitry 86 may provide power from a power source. The circuitry may include a switch that may be operable to vibrate the vibratory element and thus the aerosolization element, and aerosolization performed in this manner may be achieved within milliseconds of operation of the switch. The circuitry may include a controller 87, for example, a microprocessor that can provide power to the vibratory element 84 to produce aerosol from the aerosolization element 70 within milliseconds or fractions of milliseconds of a signal to do so. For example, aerosol production may begin within about .02 to about 50 milliseconds of such a signal and may stop within about .02 to about 50 milliseconds from the cessation of a first signal or a second signal either of which may act as a trigger to turn of aerosolization.
Similarly, aerosol production may begin and end within about .02 milliseconds to about 20 milliseconds of such respective signaling. Likewise, aerosol production may begin and end within about .02 milliseconds to about 2 milliseconds of such respective signaling. Further, this manner of aerosolization provides full aerosolization with a substantially uniform particle size of low velocity mist 79 being produced effectively instantaneously with operation of the switch.
circuitry 86 may provide power from a power source. The circuitry may include a switch that may be operable to vibrate the vibratory element and thus the aerosolization element, and aerosolization performed in this manner may be achieved within milliseconds of operation of the switch. The circuitry may include a controller 87, for example, a microprocessor that can provide power to the vibratory element 84 to produce aerosol from the aerosolization element 70 within milliseconds or fractions of milliseconds of a signal to do so. For example, aerosol production may begin within about .02 to about 50 milliseconds of such a signal and may stop within about .02 to about 50 milliseconds from the cessation of a first signal or a second signal either of which may act as a trigger to turn of aerosolization.
Similarly, aerosol production may begin and end within about .02 milliseconds to about 20 milliseconds of such respective signaling. Likewise, aerosol production may begin and end within about .02 milliseconds to about 2 milliseconds of such respective signaling. Further, this manner of aerosolization provides full aerosolization with a substantially uniform particle size of low velocity mist 79 being produced effectively instantaneously with operation of the switch.
[0080] The switch, described above, may be operable by a pressure transducer, which may be positioned in the mouthpiece of the nebulizer. The pressure transducer may be in electrical communication with the circuitry, and a microprocessor may also be in electrical communication with the circuitry, and the microprocessor may interpret electrical signals from the pressure transducer, and may also operate the switch to begin aerosolization. In this manner, nebulization can begin substantially instantaneously with the inhalation of a user upon the mouthpiece. An example of such a sensor switch can be found in co-assigned and co-pending U.S. application Ser. No. 09/705,063 assigned to the present assignee.
[0081] Another transducer may be used to sense the absence or presence of liquid in the reservoir, by sensing, for example, a difference between vibration characteristics of the aerosolization element, such as, for example, differences in frequency or amplitude, between wet vibration and substantially dry vibration. In this manner, the circuitry, may, for example by way of the microprocessor, turn the vibration off when there is essentially no more liquid to aerosolize, i.e., when the end of the dose has been achieved, thus minimizing operation of the aerosolization element in a dry state. Likewise, the switch may prevent vibration prior to delivery of a subsequent dose into the reservoir. An example of such a switch is shown in co-assigned and co-pending U.S. application Ser. No. 09/805,498.
Exemplary Nebulizer-Filter Configurations [0082] Fig. 9 shows an exploded view of a nebulizer 902 coupled to a filter 904 according to embodiments of the invention. This configuration of the nebulizer 902 and filter 904 may be part of an off-ventilator apparatus for delivering aerosolized medicament to the patient.
The filter 904 may be sandwiched between a first holding element 906, which has a nebulizer port 908 to accept the nebulizer 902, and a second holding element 910, which has a port 912 to accept a mouthpiece, facemask, nose plugs, etc. The first holding element 906 may have one or more openings that permit filtered gases passing through filter 904 to escape into the surrounding environment. Element 906 may also have gas inlet 914 that can sealingly engage with a compressed respiratory gas source (e.g., oxygen, air, etc.) or pump (not shown). The second holding element 910 may have a pressure port 916 that can sealingly engage with a pressure sensor (not shown) that measures the gas pressure in the apparatus.
Exemplary Nebulizer-Filter Configurations [0082] Fig. 9 shows an exploded view of a nebulizer 902 coupled to a filter 904 according to embodiments of the invention. This configuration of the nebulizer 902 and filter 904 may be part of an off-ventilator apparatus for delivering aerosolized medicament to the patient.
The filter 904 may be sandwiched between a first holding element 906, which has a nebulizer port 908 to accept the nebulizer 902, and a second holding element 910, which has a port 912 to accept a mouthpiece, facemask, nose plugs, etc. The first holding element 906 may have one or more openings that permit filtered gases passing through filter 904 to escape into the surrounding environment. Element 906 may also have gas inlet 914 that can sealingly engage with a compressed respiratory gas source (e.g., oxygen, air, etc.) or pump (not shown). The second holding element 910 may have a pressure port 916 that can sealingly engage with a pressure sensor (not shown) that measures the gas pressure in the apparatus.
[0083] Figs. 10A-B show the above-described nebulizer-filter configuration in operation during the inhalation (Fig. 10A) and exhalation (Fig. 10B) phases of a patient's breathing cycle. During inhalation, pressurized gas passes through gas inlet 914 and filter 904 into an area where the gases are mixed with aerosolized medicament generated by nebulizer 902.
The aerosol and gas mixture then flow through port 912 and into the patient's lungs. In the exhalation phase, gases respired by the patient enter the apparatus through port 912 and exit through the openings in holding element 906 after being filtered through the filter 904.
The aerosol and gas mixture then flow through port 912 and into the patient's lungs. In the exhalation phase, gases respired by the patient enter the apparatus through port 912 and exit through the openings in holding element 906 after being filtered through the filter 904.
[0084] The pressure in the apparatus may be monitored throughout the breathing cycle with a pressure sensor coupled to pressure port 916. The pressure sensor (not shown) may generate an analog or digital electronic signal containing information about the pressure level in the apparatus. This signal may be used to control the amount of aerosolized medicament and/or gases entering the apparatus over the course of the patient's breathing cycle. For example, when the pressure in the apparatus decreases as the patient inhales, the pressure signal may cause the nebulizer 902 to add aerosolized medicament to the apparatus, and/or cause the gas source or pump to add gas through inlet 914. Then, when the pressure in the apparatus increases as the patient exhales, the pressure signal may cause the nebulizer 902 to stop adding aerosolized medicament to the apparatus, and/or cause the gas source or pump to stop adding gas through inlet 914. Controlling the aerosol and/or gas flow based on the patient's breathing cycle, i.e., phasic delivery of the gases and aerosols, will be described in additional detail below.
Exemplary Aerosol Chamber [0085] Embodiments of the invention may include a chamber 1102 that can hold gas and aerosol mixtures for delivery to the patient's lungs. The chamber may be used in both on-ventilator and off-ventilator configurations. The expanded volume within the chamber reduces the surface area to volume ratio at the patient interface end of the system, which can increase the aerosol delivery efficiency. Figs. 11A-B show an embodiment of such a chamber, with flow paths for gases and aerosols being inhaled and exhaled by a patient. The chamber 1102 may include a plurality of ports, including a gas inlet port 1104 that can receive gases from a ventilator, pump, and/or compressed gas source (e.g., a tank of compressed air, oxygen, etc.). The chamber 1102 may also include a second port 1106 that can receive a nebulizer (not shown), and a third port 1108 that can receive an endpiece a mouthpiece, facemask, etc.).
Exemplary Aerosol Chamber [0085] Embodiments of the invention may include a chamber 1102 that can hold gas and aerosol mixtures for delivery to the patient's lungs. The chamber may be used in both on-ventilator and off-ventilator configurations. The expanded volume within the chamber reduces the surface area to volume ratio at the patient interface end of the system, which can increase the aerosol delivery efficiency. Figs. 11A-B show an embodiment of such a chamber, with flow paths for gases and aerosols being inhaled and exhaled by a patient. The chamber 1102 may include a plurality of ports, including a gas inlet port 1104 that can receive gases from a ventilator, pump, and/or compressed gas source (e.g., a tank of compressed air, oxygen, etc.). The chamber 1102 may also include a second port 1106 that can receive a nebulizer (not shown), and a third port 1108 that can receive an endpiece a mouthpiece, facemask, etc.).
[0086] Port 1108 may include a valve 1110 that can change the fluid flow path through the port 1108 depending on phase of a patient's breathing cycle. For example, during an inhalation phase (Fig. 11A), valve 1100 may be pushed away from the chamber 1102, channeling the gases and aerosols to flow around the ends of the valve into the endpiece (not shown), and ultimately into the patient's lungs. Then, during an exhalation phase (Fig. 11B), the valve 1110 is pushed by the patient's respiring gases to close port 1108, forcing the gases through openings 1112 and filters 1116 before exiting the filter housing 1117 into the surrounding atmosphere. The filter housing 1117 may include perforations that allow exhaled gases to exit and/or be constructed from gas permeable materials through which exhaled gas may diffuse.
Exemplary Medicaments [0087] Embodiments of the invention contemplate a variety of medicaments that can be aerosolized and delivered to a patient's lungs. These medicaments may include antibiotics such as aminoglycosides, 0-lactams, and quinolines, among others. The aminoglycosides may include amikacin, gentamycin, kanamycin, streptomycin, neomycin, netilmicin, and tobramycin, among other aminoglycosides. Other medicaments may also be used, including anti-oxidants, bronchodilators, corticosteroids, leukotrienes, prostacyclins, protease inhibitors, and surfactants, among other medicaments. Table 1 lists classes of medicaments and some of the aliments they may be used to treat in their aerosolized state.
Table 1: Classes of Aerosolizable Medicaments Medicament Class Aliments Treated Dosing Duration of Treatment Anti-oxidants RDS, Prevention of BPD, ALI, 1-4 per day Duration of ARDS ventilation Bronchodilators Asthma, COPD, ARDS, RDS 1-4 per day As needed Corticosteroids Asthma, COPD, BPD 1-2 per day Duration of ventilation Leukotrienes or Immunodeficiency, COPD, 1-4 per day 5-14 days related agonists Treatment/prevention of pneumonia or RSV infection Prostacyclin or PPHN, Secondary pulmonary Continuous TBD
related analogues hypertension, Post-cardiac surgery, ARDS
Protease inhibitors AECOPD, ARDS, RDS, BPD 1-2 per day 5-14 days Surfactants RDS, Prevention of BPD, ARDS 1-2 per day TBD
AECOPD: acute exacerbation of COPD
ALT: Acute lung injury ARDS: Acute respiratory distress syndrome BPD: Bronchopulmonary dysplasia COPD: chronic obstructive pulmonary disease PPIIN: persistent pulmonary hypertension RDS: Respiratory distress syndrome (also known as infant respiratory distress syndrome) RSV: Respiratory syncytial virus Exemplary Phasic Delivery Methods [0088] Figs. 12A-C show graphs of various modes of aerosolization over the course of breathing cycles. Fig. 12A shows a continuous aerosolization mode where aerosolized medicament is generated a constant rate throughout the breathing cycle.
Continuous (i.e., aphasic) generation modes typically have about 10% to about 15% aerosol delivery efficiency. Fig 12B shows a phasic delivery mode where aerosolized medicament is administered for substantially all of the inhalation phase of the breathing cycle. These modes typically have about 15% to about 25% efficiency. Fig. 12C shows another phasic delivery mode where the aerosolized medicament is administered during a predetermined portion of the inhalation phase beginning, for example, at the onset of inhalation. It has been discovered that these modes typically have delivery efficiencies between about 60% to about 80%, by weight, of the total amount of medicament that is aerosolized.
Exemplary Medicaments [0087] Embodiments of the invention contemplate a variety of medicaments that can be aerosolized and delivered to a patient's lungs. These medicaments may include antibiotics such as aminoglycosides, 0-lactams, and quinolines, among others. The aminoglycosides may include amikacin, gentamycin, kanamycin, streptomycin, neomycin, netilmicin, and tobramycin, among other aminoglycosides. Other medicaments may also be used, including anti-oxidants, bronchodilators, corticosteroids, leukotrienes, prostacyclins, protease inhibitors, and surfactants, among other medicaments. Table 1 lists classes of medicaments and some of the aliments they may be used to treat in their aerosolized state.
Table 1: Classes of Aerosolizable Medicaments Medicament Class Aliments Treated Dosing Duration of Treatment Anti-oxidants RDS, Prevention of BPD, ALI, 1-4 per day Duration of ARDS ventilation Bronchodilators Asthma, COPD, ARDS, RDS 1-4 per day As needed Corticosteroids Asthma, COPD, BPD 1-2 per day Duration of ventilation Leukotrienes or Immunodeficiency, COPD, 1-4 per day 5-14 days related agonists Treatment/prevention of pneumonia or RSV infection Prostacyclin or PPHN, Secondary pulmonary Continuous TBD
related analogues hypertension, Post-cardiac surgery, ARDS
Protease inhibitors AECOPD, ARDS, RDS, BPD 1-2 per day 5-14 days Surfactants RDS, Prevention of BPD, ARDS 1-2 per day TBD
AECOPD: acute exacerbation of COPD
ALT: Acute lung injury ARDS: Acute respiratory distress syndrome BPD: Bronchopulmonary dysplasia COPD: chronic obstructive pulmonary disease PPIIN: persistent pulmonary hypertension RDS: Respiratory distress syndrome (also known as infant respiratory distress syndrome) RSV: Respiratory syncytial virus Exemplary Phasic Delivery Methods [0088] Figs. 12A-C show graphs of various modes of aerosolization over the course of breathing cycles. Fig. 12A shows a continuous aerosolization mode where aerosolized medicament is generated a constant rate throughout the breathing cycle.
Continuous (i.e., aphasic) generation modes typically have about 10% to about 15% aerosol delivery efficiency. Fig 12B shows a phasic delivery mode where aerosolized medicament is administered for substantially all of the inhalation phase of the breathing cycle. These modes typically have about 15% to about 25% efficiency. Fig. 12C shows another phasic delivery mode where the aerosolized medicament is administered during a predetermined portion of the inhalation phase beginning, for example, at the onset of inhalation. It has been discovered that these modes typically have delivery efficiencies between about 60% to about 80%, by weight, of the total amount of medicament that is aerosolized.
[0089] Embodiments of the invention take advantage of this discovery by controlling delivery to a predetermined percentage of the breathing cycle, such as a predetermined percentage of the inhalation phase of the breathing cycle, to provide greater delivery efficiency than either continuous delivery or delivery during the entire inhalation phase.
Embodiments of the invention also take advantage of the surprising discovery that the percentage of increase in efficiency in delivery for such a predetermined portion of the inhalation phase over delivery during the entire inhalation phase is itself greater than the increase in efficiency of delivery during the inhalation phase compared to aphasic administration of the aerosol.
Embodiments of the invention also take advantage of the surprising discovery that the percentage of increase in efficiency in delivery for such a predetermined portion of the inhalation phase over delivery during the entire inhalation phase is itself greater than the increase in efficiency of delivery during the inhalation phase compared to aphasic administration of the aerosol.
[0090] Phasic delivery methods may include measuring the characteristics of a patient's inhaled breath, typically a tidal breath, and using the measurements to control the operation of the aerosol generator. Fig. 13 provides a simplified flowchart that illustrates some of the steps for phasic delivery of an aerosolized medicament according to embodiments of the invention. Phasic delivery methods may include having a patient can take one or more breaths 1320, and measuring the characteristics of the breath 1322. The breathing characteristics that can be measured include, but are not limited to, a breathing pattern, peak inspiratory flow rate, breathing rate, exhalation parameters, regularity of breathing, tidal volume, and the like and can estimate a user's tidal volume based on such information.
[0091] The user can take another tidal breath and the aerosol generator can be operated based on the measured characteristics of the tidal breath 1324. It should be appreciated however, that instead of a tidal breath, the person can take other types of breath.
Alternatively, the controller may base the timing of operation of the aerosol generator so that aerosol is generated at specific time periods within a breathing cycle. For example, the controller may operate the aerosol generator for the first 50 percent of inspiration.
Alternatively, the controller may operate the aerosol generator to generate aerosol after a portion of inhalation has taken place and to cease producing aerosol after another portion of inhalation has taken place. For example, the controller may cause aerosol to be generated beginning after 20% of the inspiration has taken place and cause aerosol production to cease after 70% of inspiration has taken place. The controller may cause aerosol production to start after, for example, after 90% of exhalation has taken place and, for example, cause aerosol production to stop after 30% of the following inspiration has taken place. By controlling the specific timing within the breathing cycle that aerosolized medication is provided into the breathing circuit, greater efficiency of drug administration can be achieved.
Alternatively, the controller may base the timing of operation of the aerosol generator so that aerosol is generated at specific time periods within a breathing cycle. For example, the controller may operate the aerosol generator for the first 50 percent of inspiration.
Alternatively, the controller may operate the aerosol generator to generate aerosol after a portion of inhalation has taken place and to cease producing aerosol after another portion of inhalation has taken place. For example, the controller may cause aerosol to be generated beginning after 20% of the inspiration has taken place and cause aerosol production to cease after 70% of inspiration has taken place. The controller may cause aerosol production to start after, for example, after 90% of exhalation has taken place and, for example, cause aerosol production to stop after 30% of the following inspiration has taken place. By controlling the specific timing within the breathing cycle that aerosolized medication is provided into the breathing circuit, greater efficiency of drug administration can be achieved.
[0092] Since some of the pharmaceuticals to be aerosolized may be more effective when delivered near the beginning of a patient's breathing cycle, while other pharmaceuticals may be more effective when delivered near the end of the patient's breathing cycle, the timing of the aerosol generation depends on the type of medicament delivered. If it is known what type of medication or drug is being delivered, the controller can select the best time during the patient's breathing cycle to deliver the aerosol, based upon a predetermined regimen for that drug that is stored in memory. As an additional benefit, an estimate of the patient's age and/or distress can be made, for example, by measuring the tidal volume and breathing rate.
Such measurements can influence the efficiency requirements of the dose per breath. These or other variables can be used in establishing various regimes for aerosol delivery, in particular delivery into the breathing circuit of a ventilator. These regimes can be stored in memory and then accessed by the controller as appropriate for a given patient condition.
Such measurements can influence the efficiency requirements of the dose per breath. These or other variables can be used in establishing various regimes for aerosol delivery, in particular delivery into the breathing circuit of a ventilator. These regimes can be stored in memory and then accessed by the controller as appropriate for a given patient condition.
[0093] For example, for a bronchodilator the best time to delivery may be half way through the inhalation phase of a breath when impaction would be reduced since inhalation flows are reducing. For steroids, it may be best to deliver towards the end of the inhalation phase of a breath. For antibiotics, it may be best to slightly pre-load, e.g., deliver aerosol during the exhalation phase, or deliver right at the start of the breath. For example, antibiotics may be delivered at the beginning of a ventilator provided inhalation, and the aerosol delivery may stop after a predetermined percentage of the inhalation has been provided. One class of antibiotics that may be administered in accordance with the present invention is the class known as the aminoglycoside class of antibiotics. This class of antibiotics has typically been administered intravenously, however, such delivery can sometimes have unwanted side effects, which may be systemic. Embodiments of the invention provide for the administration of antibiotics, such as aminoglycosides including amikacin by delivering them in aerosolized form into the breathing circuit of a patient on a ventilator.
In this manner, amikacin can be used to treat pulmonary infection conditions that typically arise when patients are mechanically ventilated, and the amikacin, or other aminoglycoside or other antibiotic, can be delivered directly to the target of treatment, the pulmonary tract, avoiding side effects that may otherwise arise from intravenous administration.
Further, because of the great cost of such drugs, far greater efficiency is achieved through this pulmonary delivery.
As noted above with reference to Fig. 12C, delivery of aerosol during a beginning percentage of the inhalation phase of a breathing cycle may yield up between about 60%
and about 80%
efficiency, a significantly higher efficacy than continuous aerosolization, or aerosolization for an entire inhalation phase of an inhalation cycle.
In this manner, amikacin can be used to treat pulmonary infection conditions that typically arise when patients are mechanically ventilated, and the amikacin, or other aminoglycoside or other antibiotic, can be delivered directly to the target of treatment, the pulmonary tract, avoiding side effects that may otherwise arise from intravenous administration.
Further, because of the great cost of such drugs, far greater efficiency is achieved through this pulmonary delivery.
As noted above with reference to Fig. 12C, delivery of aerosol during a beginning percentage of the inhalation phase of a breathing cycle may yield up between about 60%
and about 80%
efficiency, a significantly higher efficacy than continuous aerosolization, or aerosolization for an entire inhalation phase of an inhalation cycle.
[0094] Embodiments of the invention provide for conducting various regimes of aerosolization, depending on the situation. For example, in Fig 14, a selection between a first, second and third regime is shown. A regime may be selected manually or automatically, for example, through the application of an algorithm that selects an operation program based on information that is either input or stored. For manual selection, a user may operate a mechanical switch to select a regime, or may enter such a selection into an electronic input device, such as a keyboard. Alternatively, the controller may automatically choose a regimen, as described above, by matching a drug code on a drug nebule with a library of drug-regimen combinations. (It should be noted that in Figs. 14-17, schematic flow charts of operation sequence algorithms are depicted. Although items therein will be referred to as steps for ease of discussion, they refer more broadly herein to states of operations or modalities in which a system may exist or cycle through. Steps depicted in a rectangle are essentially states of operation, actions or modalities. Steps depicted in diamonds indicate either a selection or the continuance of the previous state of operation, action or modality until a predetermined condition is satisfied. Two successive diamonds refer to satisfaction of a first condition and of a second condition respectively, the second of which may be a subset of the first.) [0095] In step 1400, a choice is made to follow a particular regime. In this case, regime I is a regime in which aerosol is generated continuously (step 1402). Regime II
provides aerosol generation during the inhalation phase only (step 1404). In this case, in step 1406, aerosol generation is set to start at the start of the inhalation phase and, in step 1408, aerosol generation is set to stop when the inhalation phase stops. In step 1410, aerosol generation begins at the start of the inhalation phase. In step 1412, when the inhalation phase ends, aerosol generation stops (step 1414).
provides aerosol generation during the inhalation phase only (step 1404). In this case, in step 1406, aerosol generation is set to start at the start of the inhalation phase and, in step 1408, aerosol generation is set to stop when the inhalation phase stops. In step 1410, aerosol generation begins at the start of the inhalation phase. In step 1412, when the inhalation phase ends, aerosol generation stops (step 1414).
[0096] Regime III provides for inhalation during a predetermined percentage of the inhalation phase (step 1416). A predetermined percentage of an inhalation (or exhalation) phase may be based on a measured time from a discrete point in the ventilator cycle, such as the instantaneous commencement of inspiratory air generation by the ventilator.
Alternatively, such predetermined percentage may be based on the time interval between successive discrete points in the ventilator, such as successive commencements of successive inhalation air generation by the ventilator. Alternatively, such percentages may be based upon air pressure in the ventilator circuit, or any other parameter. With respect to Regime III, in this case, in step 1418, a first predetermined point is set to correspond with the completion of a first predetermined percent of the inhalation. In step 1420, a second predetermined point is set to correspond to a second predetermined percent of inhalation percent being completed.
For example, as described above, the first predeteimined point may correspond to 20% of the inhalation phase being completed, and the second predetermined point may correspond to a point at which 70% of that same inhalation has taken place. In step 1422, aerosol generation begins at the first predetermined point in the inhalation phase. In step 1424, when the second predetermined point is reached, the controller carries out step 1414 and stops the aerosol generation.
Alternatively, such predetermined percentage may be based on the time interval between successive discrete points in the ventilator, such as successive commencements of successive inhalation air generation by the ventilator. Alternatively, such percentages may be based upon air pressure in the ventilator circuit, or any other parameter. With respect to Regime III, in this case, in step 1418, a first predetermined point is set to correspond with the completion of a first predetermined percent of the inhalation. In step 1420, a second predetermined point is set to correspond to a second predetermined percent of inhalation percent being completed.
For example, as described above, the first predeteimined point may correspond to 20% of the inhalation phase being completed, and the second predetermined point may correspond to a point at which 70% of that same inhalation has taken place. In step 1422, aerosol generation begins at the first predetermined point in the inhalation phase. In step 1424, when the second predetermined point is reached, the controller carries out step 1414 and stops the aerosol generation.
[0097] Similarly, as noted above, other regimes may be followed, for example, in which aerosol generation begins during the inhalation phase and ends during the exhalation phase, or begins during exhalation and ends during that exhalation, or begins during exhalation and ends in the subsequent breath cycle, for example, at a predetermined point in the subsequent inhalation phase. Accordingly, turning to Fig. 15, a selection may be made, at step 1430, between regimes II (step 1432) and III (step 1434) as described above, and another regime, regime IV (steps 1436 - 1442), which is also available for selection. In regime IV, aerosol generation may begin at a first predetermined point (step 1436), and this first predetermined point may be after a predetermined percentage of the inhalation phase has taken place, or it may be a predetermined point after the inhalation phase has been completed.
For example, this point may be a predetermined point after a predetermined percent of the exhalation phase has taken place, or may be a predetermined point prior to the start of the subsequent inhalation phase. Aerosol generation may stop during exhalation (regime IVa, step 1438), at the completion of exhalation (regime IVb, step 1440), or aerosol generation may continue into the next breath cycle (regime IVc, step 1442), and stop, for example, after a predetermined point during the subsequent inhalation phase.
For example, this point may be a predetermined point after a predetermined percent of the exhalation phase has taken place, or may be a predetermined point prior to the start of the subsequent inhalation phase. Aerosol generation may stop during exhalation (regime IVa, step 1438), at the completion of exhalation (regime IVb, step 1440), or aerosol generation may continue into the next breath cycle (regime IVc, step 1442), and stop, for example, after a predetermined point during the subsequent inhalation phase.
[0098] In this example, with the controller having a selection choice between operation sequences corresponding to regimes II, III and IV, schematic representation of the operation sequences are shown in Fig. 16. In step 1450, a regime is selected. In step 1452, the aerosol generator controller selects an operation sequence based on selected regime.
In step 1454, the controller receives a signal indicating that ventilator has begun to supply an inhalation phase. The signal, as described above, may be a signal provided directly by the ventilator.
Alternatively, the signal may be provided by a sensor, and such sensor may sense the commencement of an inhalation phase provided by the ventilator, as described above, by sensing a pressure change in the breathing circuit. In step 1456, the controller carries out selected operation sequence. In the case of regime II (step 1458), the controller turns on aerosol generator upon commencement of inhalation phase provided by the ventilator. The controller continues to operate the aerosol generator until a point at which the inhalation phase completed (step 1460). In step 1462, controller turns off aerosol generator.
In step 1454, the controller receives a signal indicating that ventilator has begun to supply an inhalation phase. The signal, as described above, may be a signal provided directly by the ventilator.
Alternatively, the signal may be provided by a sensor, and such sensor may sense the commencement of an inhalation phase provided by the ventilator, as described above, by sensing a pressure change in the breathing circuit. In step 1456, the controller carries out selected operation sequence. In the case of regime II (step 1458), the controller turns on aerosol generator upon commencement of inhalation phase provided by the ventilator. The controller continues to operate the aerosol generator until a point at which the inhalation phase completed (step 1460). In step 1462, controller turns off aerosol generator.
[0099] In the case of regime III, the controller does not take any action to begin aerosol generation, until a predetermined point in the inhalation phase, corresponding to a percentage of the inhalation phase being completed (step 1464). In step 1466, at a predetermined point in the inhalation phase, the controller turns on aerosol generator. In step 1468, aerosol generation continues until a second predetermined point inhalation phase, corresponding to a second percentage point of completion of the inhalation phase. At this point, the controller carries out step 1462 and turns off aerosol generator. With respect to regime IV, aerosol generation begins after a predetermined point of completion of the inhalation phase (step 1464) and this point may be predetermined to occur after the inhalation phase has been completed and the exhalation phase has begun (step 1470). In step 1472, the controller turns the aerosol generator on to begin aerosolization. Variations can be made as to the point at which the aerosol generation is turned off. If it is desired that aerosol generation be completed before the completion of the exhalation phase (regime IVa), then aerosol generation may continue until a predetermined point prior to the subsequent inhalation (step 1476). Alternatively, it may be desirable to continue aerosolization until the end of exhalation, which may correspond to the point of commencement of the subsequent inhalation, as in regime IVb (step 1478). Alternatively, it may be desired to follow a regimen such as regime IVc, where aerosol generation continues through into the subsequent breath cycle (step 1480), until, for example, a predetermined percent of the subsequent inhalation phase has been completed (step 1482). In these regimes, aerosolization will continue until the satisfaction of these conditions (step 1476 for regime IVa, step 1478 for regime IVb or step 1482 for regime IVc), at which point the controller carries out step 1462 and stops the aerosol generator. The process may continue with the next signal indicating that the ventilator has begun to provide an inhalation phase, step 1454.
[0100] Further, the choice of which operating sequence to follow may rely at least in part on the identity of a drug to be administered, which information can be considered by the controller as described above. In addition, it should be appreciated that modifications may be made to these examples without departing from the present invention. For example, a system may be configured, or a method may be carried out, to be able to select more than three initial regimes to follow. For example, regimes I, II, III and IV as described above may be simultaneously selectable. Further, various steps may be altered; for example, some steps may not be discrete steps. Thus, step 1456 may not be a discrete step but rather the following of an operation sequence according to a selected regime. Similarly, the order of the steps may be changed, such as the controller may select an operating sequence (step 1452) after receiving a signal that the ventilator has commenced to provide an inhalation phase (step 1454). Steps may also be combined, such as, for example, in regime IV steps 1464 and 1470 may be combined as a single step, as these two steps represent successive criteria for the determining a single first predetermined point has been met. Likewise, step 1474 may be combined with steps 1476, 1478 or 1480, as step 1474 is the predicate for the condition test specified in each of the other successive tests, steps 1476, 1478 or 1480. The algorithm examples may be altered to form other operating sequences. For example, an operating sequence may call for the controller to start aerosol generation at the start of the inhalation cycle provided by the nebulizer, as in regime II, at step 1458, and turn off the aerosol generator at a point at which a predetermined percentage of the inhalation phase has been completed, as in regime III, step 1468 (and step 1462). In a similar manner, other criteria may be used to trigger the turning on or off of the aerosol generator. For example, as described above, the start of aerosolization may be triggered by the sensing of a particular pressure or change in pressure in the ventilator circuit, and may end by following the turning off sequence of regimes III (steps 1468 and 1462) or IV (steps 1474, 1476, 1478 or 1480 and 1482, followed by step 1462, as described above.
[0101] Fig. 17 is a schematic representation of an algorithm by which an operating sequence, for providing nebulized drug to a patient receiving air from a ventilator, may be chosen based on the combination of a plurality of independent sets of information, in this case, drug identity and a signal from the ventilator. In step 1700, a library of drug regimes is provided, the library based on various drugs that may be administered. In step 1702, the identity of a particular drug is provided to the system, and this may be provided, as described above, by a marker on a nebule containing the drug, the marker being read by the system. In step 1704, the controller looks up a regime from the library of stored regimes to select a .
regime based on the particular drug to be administered. In step 1706, the controller receives a signal from the ventilator. In step 1708, the controller then chooses an operation sequence based in part on the drug identity and drug regime and in part on the independent information provided by the signal from the ventilator. In step 1710, the controller carries out the operation sequence, which may be producing aerosol at a predetermined interval in the ventilation cycle based on the drug and the regime provided for the drug factored in with the inhalation cycle of the ventilator. These descriptions are illustrative, and accordingly, the order of the steps may be altered, and other variations, additions and modifications, as described above, may be made still in accordance with the present invention.
regime based on the particular drug to be administered. In step 1706, the controller receives a signal from the ventilator. In step 1708, the controller then chooses an operation sequence based in part on the drug identity and drug regime and in part on the independent information provided by the signal from the ventilator. In step 1710, the controller carries out the operation sequence, which may be producing aerosol at a predetermined interval in the ventilation cycle based on the drug and the regime provided for the drug factored in with the inhalation cycle of the ventilator. These descriptions are illustrative, and accordingly, the order of the steps may be altered, and other variations, additions and modifications, as described above, may be made still in accordance with the present invention.
[0102] The phasic delivery methods outlined above may also be practiced with additional systems such as continuous positive airway pressure ("CPAP") systems, such as the ones described in U.S. Pat. App. Serial No. 10/828,765, filed April 20,2004, U.S.
Pat. App. Serial No. 10/883,115, filed June 30, 2004, U.S. Pat. App. Serial No. 10/957,321, filed September 9, 2004.
EXPERIMENTAL
Pat. App. Serial No. 10/883,115, filed June 30, 2004, U.S. Pat. App. Serial No. 10/957,321, filed September 9, 2004.
EXPERIMENTAL
[0103] Delivery efficacy tests were conducted with an on-ventilator PDDS
aerosolizing an aqueous solution of amikacin sulfate. The PDDS ventilator circuit configuration was similar to the one shown and described in Fig. 2 above. A 400 mg dose of the amikacin was run through the PDDS. The PDDS was configured to deliver the aerosolized medicament by a phasic delivery regime similar to the one shown in Fig. 12C. The medicament dose was delivered over the course of about 50 to about 60 minutes.
aerosolizing an aqueous solution of amikacin sulfate. The PDDS ventilator circuit configuration was similar to the one shown and described in Fig. 2 above. A 400 mg dose of the amikacin was run through the PDDS. The PDDS was configured to deliver the aerosolized medicament by a phasic delivery regime similar to the one shown in Fig. 12C. The medicament dose was delivered over the course of about 50 to about 60 minutes.
[0104] Table 2 presents efficiency data for the delivery of aerosolized medicament to through systems according to embodiments of the invention. In the experimental setup, aerosolized droplets deposited on an inspiratory filter placed at a patient end interface are weighed and compared to the total weight of the dose of medicament that was aerosolized.
The percentage of a dose deposited on the inspiratory filter represents the fraction of the total aerosolized dose that would be inhaled by a patient, and thus quantifies the efficiency of the system.
Table 2 - Percent of Dose Deposited on Inspiratory Filter Percent Standard Run No. Deposited on Mean %RSD
Deviation Filter 1 69%
2 75%
3 75%
4 77% 71% 0.04 6%
5 69%
6 66%
7 68%
The percentage of a dose deposited on the inspiratory filter represents the fraction of the total aerosolized dose that would be inhaled by a patient, and thus quantifies the efficiency of the system.
Table 2 - Percent of Dose Deposited on Inspiratory Filter Percent Standard Run No. Deposited on Mean %RSD
Deviation Filter 1 69%
2 75%
3 75%
4 77% 71% 0.04 6%
5 69%
6 66%
7 68%
[0105] Table 2 shows the efficiencies of 7 runs for a system according to an embodiment of the invention had a mean efficiency of 71% 6%. This efficiency level is well above conventional systems for the delivery of aerosolized medicaments, where the efficiency levels are typically 10% or less.
[0106] The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole. Additionally, a number of well known processes and elements have not been described in order to avoid unnecessarily obscuring the present invention.
[0107] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included.
[0108] As used herein and in the appended claims, the singular forms "a", "an", and "the"
include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a process" includes a plurality of such processes and reference to "the electrode"
includes reference to one or more electrodes and equivalents thereof known to those skilled in the art, and so forth.
include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a process" includes a plurality of such processes and reference to "the electrode"
includes reference to one or more electrodes and equivalents thereof known to those skilled in the art, and so forth.
[0109] Also, the words "comprise," "comprising," "include," "including," and "includes"
when used in this specification and in the following claims are intended to specify the presence of stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, acts, or groups.
when used in this specification and in the following claims are intended to specify the presence of stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, acts, or groups.
Claims (8)
1. A nebulizing element for coupling to a T-piece, the nebulizing element comprising:
a base for coupling to the T-piece;
a conical shaped reservoir orientated at an angle between about 10 and about degrees with respect to the base, and an aerosol generator including a vibratory element that is configured to vibrate an aerosolization element having a plurality of apertures, the aerosolization element comprising a first face and a second face, the plurality of apertures extending between the first face and second face.
a base for coupling to the T-piece;
a conical shaped reservoir orientated at an angle between about 10 and about degrees with respect to the base, and an aerosol generator including a vibratory element that is configured to vibrate an aerosolization element having a plurality of apertures, the aerosolization element comprising a first face and a second face, the plurality of apertures extending between the first face and second face.
2. The nebulizing element of claim 1, further comprising a power inlet.
3. A nebulizing element comprising:
a conical shaped reservoir orientated at an angle between about 10 and about degrees with respect to a base of the nebulizing element, and an aerosol generator including a vibratory element that is configured to vibrate an aerosolization element having a plurality of apertures, the aerosolization element comprising a first face and a second face, the plurality of apertures extending between the first face and second face.
a conical shaped reservoir orientated at an angle between about 10 and about degrees with respect to a base of the nebulizing element, and an aerosol generator including a vibratory element that is configured to vibrate an aerosolization element having a plurality of apertures, the aerosolization element comprising a first face and a second face, the plurality of apertures extending between the first face and second face.
4. The nebulizing element of claim 3, wherein the nebulizing element is coupleable to a ventilator breathing circuit or a T-piece.
5. The nebulizing element of claim 3, further comprising a power inlet.
6. The nebulizing element of claim 3, further comprising a reservoir cap.
7. The nebulizing element of claim 3, wherein the reservoir holds a volume from about 1 mL to about 10 mL.
8. The nebulizing element of claim 3, wherein the aerosolization element comprises palladium.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/090,328 | 2005-03-24 | ||
US11/090,328 US7971588B2 (en) | 2000-05-05 | 2005-03-24 | Methods and systems for operating an aerosol generator |
PCT/US2006/010278 WO2006102345A2 (en) | 2005-03-24 | 2006-03-22 | Methods and systems for operating an aerosol generator |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2599018A1 CA2599018A1 (en) | 2006-09-28 |
CA2599018C true CA2599018C (en) | 2014-05-13 |
Family
ID=36588910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2599018A Active CA2599018C (en) | 2005-03-24 | 2006-03-22 | Methods and systems for operating an aerosol generator |
Country Status (13)
Country | Link |
---|---|
US (2) | US7971588B2 (en) |
EP (1) | EP1868570B1 (en) |
JP (1) | JP5008093B2 (en) |
KR (1) | KR101301163B1 (en) |
CN (1) | CN101146517B (en) |
AU (1) | AU2006227168B2 (en) |
BR (1) | BRPI0609725B8 (en) |
CA (1) | CA2599018C (en) |
ES (1) | ES2642041T3 (en) |
IL (1) | IL186162A (en) |
MX (1) | MX2007011786A (en) |
NZ (2) | NZ595112A (en) |
WO (1) | WO2006102345A2 (en) |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW465235B (en) | 1998-09-17 | 2001-11-21 | United Video Properties Inc | Electronic program guide with digital storage |
US7971588B2 (en) | 2000-05-05 | 2011-07-05 | Novartis Ag | Methods and systems for operating an aerosol generator |
ZA200306564B (en) * | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
US7607436B2 (en) * | 2002-05-06 | 2009-10-27 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
US7334580B2 (en) * | 2002-05-07 | 2008-02-26 | Smaldone Gerald C | Methods, devices and formulations for targeted endobronchial therapy |
US6966649B2 (en) * | 2002-08-12 | 2005-11-22 | John H Shadduck | Adaptive optic lens system and method of use |
US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
US7849853B2 (en) * | 2003-02-11 | 2010-12-14 | Trudell Medical International | Ventilator circuit and the method for the use thereof |
US7191780B2 (en) * | 2003-09-22 | 2007-03-20 | Comedica Incorporated | Continuous high-frequency oscillation breathing treatment apparatus |
US8375947B2 (en) * | 2003-11-17 | 2013-02-19 | Novartis Ag | Introducing aerosol into a ventilator |
EP1755720A1 (en) * | 2004-05-20 | 2007-02-28 | Discovery Laboratories, Inc. | Methods , systems and devices for noninvasive pulmonary delivery |
FR2875138B1 (en) | 2004-09-15 | 2008-07-11 | Mallinckrodt Dev France Sa | CONTROL METHOD FOR A HEATING HUMIDIFIER |
US8028697B2 (en) | 2005-04-28 | 2011-10-04 | Trudell Medical International | Ventilator circuit and method for the use thereof |
EP1893273B1 (en) | 2005-05-18 | 2014-06-25 | Nektar Therapeutics | Adapter for use with aerosolization device for endobronchial therapy |
CN101208123B (en) | 2005-05-25 | 2012-09-19 | 亚罗擎公司 | Vibration systems and methods |
US20100126502A1 (en) * | 2005-08-23 | 2010-05-27 | Aerogen, Inc. | Self-sealing t-piece and valved t-piece |
KR101424518B1 (en) | 2005-09-29 | 2014-08-06 | 노바르티스 아게 | Antibiotic formulations, unit doses, kits, and methods |
LT1962805T (en) | 2005-12-08 | 2016-10-25 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
US8460223B2 (en) | 2006-03-15 | 2013-06-11 | Hill-Rom Services Pte. Ltd. | High frequency chest wall oscillation system |
JP5600432B2 (en) * | 2006-04-06 | 2014-10-01 | インスメッド, インコーポレイテッド | Coacervation-induced liposome encapsulation method and preparation thereof |
DE102006017002B3 (en) * | 2006-04-11 | 2007-01-11 | Pari GmbH Spezialisten für effektive Inhalation | Nebulizer for inhalation therapy comprises compressed gas outlet openings arranged in a row to which are assigned fluid outlet openings forming a nozzle with the gas outlet openings |
US7909033B2 (en) * | 2006-05-03 | 2011-03-22 | Comedica Incorporated | Breathing treatment apparatus |
EP2037999B1 (en) | 2006-07-07 | 2016-12-28 | Proteus Digital Health, Inc. | Smart parenteral administration system |
US20080027372A1 (en) * | 2006-07-31 | 2008-01-31 | Stanley Baldwin | Medication port for a ventilation machine |
MX2009001944A (en) | 2006-08-21 | 2009-04-16 | Trudell Medical Int | Respiratory muscle endurance training device and method for the use thereof. |
US20080230053A1 (en) * | 2006-09-15 | 2008-09-25 | Board Of Regents, The University Of Texas System | Pulse drug nebulization systems, formulations therefore, and methods of use |
US8051854B2 (en) | 2006-09-15 | 2011-11-08 | Comedica Incorporated | Continuous high-frequency oscillation breathing treatment apparatus |
NL2000309C2 (en) | 2006-11-09 | 2008-05-13 | Indes Holding Bv | System for artificial respiration of people. |
JP2008199905A (en) * | 2007-02-16 | 2008-09-04 | Snow Brand Milk Prod Co Ltd | Improving agent for survivability of lactic acid bacterium |
US20090241948A1 (en) * | 2007-03-28 | 2009-10-01 | Dermot Joseph Clancy | Humidification in breathing circuits |
WO2008117264A1 (en) * | 2007-03-28 | 2008-10-02 | Stamford Devices Limited | Insufflation of body cavities |
US8371299B2 (en) * | 2007-04-19 | 2013-02-12 | Respironics Respiratory Drug Delivery | Ventilator aerosol delivery |
US8151794B2 (en) | 2007-04-24 | 2012-04-10 | Trudell Medical International | Aerosol delivery system |
US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9566397B2 (en) * | 2007-05-15 | 2017-02-14 | Joseph Dee Faram | Small-volume nebulizers and methods of use thereof |
US9050434B2 (en) | 2007-05-18 | 2015-06-09 | Comedica Incorporated | Lung therapy device |
US10293123B2 (en) | 2007-05-23 | 2019-05-21 | Shin Nippon Biomedical Laboratories, Ltd. | Test substance administration system for animal experiment |
US8261738B2 (en) * | 2007-07-24 | 2012-09-11 | Respironics Respiratory Drug Delivery (Uk) Ltd. | Apparatus and method for maintaining consistency for aerosol drug delivery treatments |
EP2022525B1 (en) * | 2007-08-02 | 2012-12-26 | Activaero GmbH | Device and system for targeting aerosolized particles to a specific area of the lungs |
EP2203155A1 (en) * | 2007-09-25 | 2010-07-07 | Novartis Ag | Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin |
JP5243548B2 (en) | 2007-10-25 | 2013-07-24 | プロテウス デジタル ヘルス, インコーポレイテッド | Fluid communication port for information systems |
US8419638B2 (en) | 2007-11-19 | 2013-04-16 | Proteus Digital Health, Inc. | Body-associated fluid transport structure evaluation devices |
EP2067497B1 (en) * | 2007-12-05 | 2017-02-15 | Vectura GmbH | Methods, systems and computer-readable products for optimizing aerosol particle administration to the lungs |
US20090188500A1 (en) * | 2008-01-29 | 2009-07-30 | Joseph Dee Faram | Combination breathing treatment method |
CA2884941C (en) | 2008-02-21 | 2017-03-14 | Martin P. Foley | Respiratory muscle endurance training device |
NZ588478A (en) * | 2008-03-17 | 2013-06-28 | Discovery Lab Inc | Ventilation circuit surrounding proximal aerosol delivery channel |
PT2285439E (en) | 2008-04-04 | 2014-03-25 | Nektar Therapeutics | Aerosolization device |
AU2013201359B2 (en) * | 2008-05-09 | 2015-09-17 | Pari Pharma Gmbh | Atomizer for Ventilation Machines and Ventilation Machine Comprising said Atomizer |
DE102008022987A1 (en) | 2008-05-09 | 2009-11-12 | Pari Pharma Gmbh | Nebulizer for respirators and ventilator with such a nebulizer |
AU2015264908B2 (en) * | 2008-05-09 | 2017-06-29 | Pari Pharma Gmbh | Nebuliser for Ventilation Machines and a Ventilation Machine Comprising such a Nebuliser |
WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
US8794234B2 (en) | 2008-09-25 | 2014-08-05 | Covidien Lp | Inversion-based feed-forward compensation of inspiratory trigger dynamics in medical ventilators |
EP2337600B1 (en) | 2008-09-26 | 2019-09-18 | Stamford Devices Limited | Supplemental oxygen delivery system |
JP2012503519A (en) * | 2008-09-26 | 2012-02-09 | スタンフォード・デバイシズ・リミテッド | Nebulizer device |
ES2402241T3 (en) | 2008-10-22 | 2013-04-30 | Trudell Medical International | Modular Spray Supply System |
EP2451519A1 (en) * | 2009-07-09 | 2012-05-16 | Koninklijke Philips Electronics N.V. | System and method for integrated paced breathing and inhalation therapy |
US9151425B2 (en) | 2009-11-02 | 2015-10-06 | Comedica Incorporated | Multiple conduit connector apparatus and method |
CN101711622A (en) * | 2009-12-03 | 2010-05-26 | 延吉吉睦泰克科技发展有限公司 | Hair-care atomization device |
SG189763A1 (en) | 2010-02-01 | 2013-05-31 | Proteus Digital Health Inc | Two-wrist data gathering system |
JP5841951B2 (en) | 2010-02-01 | 2016-01-13 | プロテウス デジタル ヘルス, インコーポレイテッド | Data collection system |
US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
ES2740964T3 (en) * | 2010-08-09 | 2020-02-07 | Fraunhofer Ges Forschung | Device and system for delivering a spray to a patient on ventilatory support |
DE102010054361B4 (en) * | 2010-12-13 | 2013-02-21 | Nli Gmbh | therapy device |
CN102553039B (en) * | 2010-12-17 | 2014-10-29 | 陈庆堂 | Medicinal powder suction nozzle and application |
US9452274B2 (en) | 2011-01-20 | 2016-09-27 | Pneumoflex Systems, Llc | Metered dose atomizer |
US9452270B2 (en) | 2011-01-20 | 2016-09-27 | Pneumoflex Systems, Llc | Nebulizer having replaceable nozzle assembly and suction line |
US9068566B2 (en) | 2011-01-21 | 2015-06-30 | Biodot, Inc. | Piezoelectric dispenser with a longitudinal transducer and replaceable capillary tube |
US8826904B2 (en) | 2011-07-12 | 2014-09-09 | Cardeas Pharma Corporation | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis |
CA2841272C (en) * | 2011-07-12 | 2019-01-15 | Alan Bruce Montgomery | Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis |
DE102012200815B3 (en) * | 2012-01-20 | 2013-01-10 | Dieter Kirsch | An inhalation support device and method for inhalation support |
CN204364581U (en) | 2012-01-24 | 2015-06-03 | 蒸汽热能公司 | Be used to provide the system of respiratory therapy |
CN108743537B (en) | 2012-05-21 | 2021-06-11 | 英斯麦德公司 | System for treating pulmonary infections |
US9713687B2 (en) * | 2012-08-21 | 2017-07-25 | Philip Morris Usa Inc. | Ventilator aerosol delivery system with transition adapter for introducing carrier gas |
RU2675859C2 (en) | 2012-11-29 | 2018-12-25 | Инсмед Инкорпорейтед | Stabilised vancomycin formulations |
US9795752B2 (en) | 2012-12-03 | 2017-10-24 | Mhs Care-Innovation, Llc | Combination respiratory therapy device, system, and method |
WO2014164997A1 (en) * | 2013-03-13 | 2014-10-09 | Teleflex Medical Incorporated | Single-piece aerosol exhalation filter and an aerosol delivery device including the same |
EP2968831B1 (en) | 2013-03-15 | 2021-06-23 | Trudell Medical International | Ventilator circuit, adapter for use in ventilator circuit and methods for the use thereof |
GB2583032B (en) * | 2013-03-15 | 2021-02-10 | Fisher & Paykel Healthcare Ltd | Components for medical circuits |
US20150000652A1 (en) * | 2013-06-26 | 2015-01-01 | General Electric Company | Gas delivery unit and breathing mask for delivering respiratory gas of a subject |
US10010692B2 (en) | 2013-07-08 | 2018-07-03 | Virginia Commonwealth University | Systems, devices, and methods for changing therapeutic aerosol size and improving efficiency of ventilation and aerosol drug delivery |
US20150020802A1 (en) * | 2013-07-17 | 2015-01-22 | Insmed Incorporated | Low resistance aerosol exhalation filter |
EP3024590B1 (en) | 2013-07-24 | 2017-08-09 | Stamford Devices Limited | Nebulizer vibrating aperture plate drive frequency control and monitoring |
US10335567B2 (en) * | 2013-08-27 | 2019-07-02 | 12th Man Technologies, Inc. | Nitric oxide upper airway delivery system and method |
US9937302B2 (en) | 2013-09-13 | 2018-04-10 | Delta Electronics, Inc. | Nebulizing device and nebulizer |
TWI539978B (en) * | 2013-09-13 | 2016-07-01 | 台達電子工業股份有限公司 | Nebulizer and medicament storage module thereof |
US10092712B2 (en) * | 2013-11-04 | 2018-10-09 | Stamford Devices Limited | Aerosol delivery system |
KR101520857B1 (en) * | 2014-01-23 | 2015-05-18 | (주)알메카 | Portable nebulizer of artificial intelligence spraying type |
EP3142643B1 (en) | 2014-05-15 | 2019-07-10 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
CN109045425A (en) * | 2014-08-01 | 2018-12-21 | 心诚镁行动医电股份有限公司 | Portable ultrasonic atomizer and its protection structure |
KR102548643B1 (en) | 2014-08-28 | 2023-06-27 | 노턴 (워터포드) 리미티드 | Compliance- assisting module for an inhaler |
EP3037120A1 (en) | 2014-12-23 | 2016-06-29 | PARI Pharma GmbH | Aerosol delivery device and operating method for the aerosol delivery device |
US10315002B2 (en) | 2015-03-24 | 2019-06-11 | Ventec Life Systems, Inc. | Ventilator with integrated oxygen production |
CN111603643B (en) | 2015-04-02 | 2023-05-23 | 希尔-罗姆服务私人有限公司 | Pressure control of breathing apparatus |
CN105126213B (en) * | 2015-08-22 | 2019-01-08 | 陈志翠 | Portable first-aid inhalation system |
US10500354B2 (en) | 2015-09-25 | 2019-12-10 | Sanmina Corporation | System and method for atomizing and monitoring a drug cartridge during inhalation treatments |
USD776278S1 (en) | 2015-10-30 | 2017-01-10 | Mallinckrodt Hospital Products IP Limited | MRI compatible therapeutic gas injector module |
CN105664329B (en) * | 2016-01-05 | 2018-09-11 | 湖南明康中锦医疗科技发展有限公司 | Can cooperative mechanical ventilation atomization system |
US11285285B2 (en) * | 2016-05-03 | 2022-03-29 | Pneuma Respiratory, Inc. | Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment |
US10773049B2 (en) | 2016-06-21 | 2020-09-15 | Ventec Life Systems, Inc. | Cough-assist systems with humidifier bypass |
US11160948B2 (en) * | 2016-06-22 | 2021-11-02 | Imam Abdulrahman Bin Faisal University | Nebulizer tubing with a port to minimize medicament loss |
CA3028604C (en) | 2016-07-08 | 2023-12-05 | Trudell Medical International | Smart oscillating positive expiratory pressure device |
DE102016112986A1 (en) * | 2016-07-14 | 2018-01-18 | Nebu-Tec Med. Produkte Eike Kern Gmbh | Inhalation method with controlled cyclic activation |
US11376391B2 (en) * | 2016-08-26 | 2022-07-05 | ResMed Pty Ltd | Respiratory pressure therapy system with nebulising humidifier |
WO2018057058A1 (en) * | 2016-09-24 | 2018-03-29 | Sanmina Corporation | System and method for atomizing and monitoring a drug cartridge during inhalation treatments |
EP3551261B1 (en) | 2016-12-09 | 2022-05-11 | Trudell Medical International | Smart nebulizer |
US11452824B2 (en) * | 2017-02-27 | 2022-09-27 | Hill-Rom Services Pte. Ltd. | Respiratory therapy filter, flow control, and patient interface apparatuses, systems, and methods |
WO2018172563A1 (en) * | 2017-03-23 | 2018-09-27 | Stamford Devices Ltd | Aerosol delivery system and method |
US10987474B2 (en) | 2017-03-23 | 2021-04-27 | Stamford Devices Ltd. | Retrofit aerosol delivery system and method |
EP3600511A1 (en) * | 2017-03-23 | 2020-02-05 | Stamford Devices Ltd | Retrofit aerosol delivery system and method |
EP4223335A3 (en) | 2017-05-19 | 2023-11-08 | Pneuma Respiratory, Inc. | Dry powder delivery device and methods of use |
KR102643190B1 (en) | 2017-06-10 | 2024-03-04 | 아이노비아 인코포레이티드 | Devices for handling fluids and delivering fluids to the eye |
US11738158B2 (en) * | 2017-10-04 | 2023-08-29 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device and methods of use |
EP3697481A4 (en) | 2017-10-17 | 2021-07-14 | Pneuma Respiratory, Inc. | Nasal drug delivery apparatus and methods of use |
JP2021502178A (en) | 2017-11-08 | 2021-01-28 | ニューマ・リスパイラトリー・インコーポレイテッド | In-line droplet delivery device with a small volume ampoule and electrically actuated by breathing and how to use |
US10342935B2 (en) | 2017-11-21 | 2019-07-09 | Caddo Medical Technologies Llc | Internal nebulizer seal and method of use |
TWD192077S (en) * | 2017-12-15 | 2018-08-01 | 微邦科技股份有限公司 | Sprayer |
CA3086890A1 (en) | 2018-01-04 | 2019-07-11 | Trudell Medical International | Smart oscillating positive expiratory pressure device |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
US10258758B1 (en) | 2018-04-20 | 2019-04-16 | Caddo Medical Technologies Llc | Flow controlled valve for a small-volume nebulizer |
CN108578856B (en) * | 2018-05-20 | 2023-07-18 | 江西中医药大学 | Sharing fragrant oxygen system |
USD894376S1 (en) * | 2018-05-23 | 2020-08-25 | Fisher & Paykel Healthcare Limited | Insufflation circuit assembly |
USD894379S1 (en) * | 2018-05-23 | 2020-08-25 | Fisher & Paykel Healthcare Limited | Insufflation circuit and filter |
US11602601B2 (en) | 2018-05-31 | 2023-03-14 | Vapotherm, Inc. | Machine proximate nebulizer |
MX2020012960A (en) * | 2018-05-31 | 2021-04-28 | Vapotherm Inc | Cannula-based vibrating mesh nebulizer. |
CN112368009A (en) | 2018-06-27 | 2021-02-12 | 呼吸治疗公司 | Inhalable compositions comprising macrocyclic immunosuppressants |
EA202092892A1 (en) | 2018-12-04 | 2021-05-27 | Брес Терапьютикс Гмбх | INHALATION COMPOSITIONS CONTAINING MACROCYCLIC IMMUNOSUPPRESSANTS |
EP3890812A1 (en) | 2018-12-04 | 2021-10-13 | PARI Pharma GmbH | Mouthpiece and nebulizer having a mouthpiece |
US20220226587A1 (en) * | 2019-05-09 | 2022-07-21 | Pneuma Respiratory, Inc. | Ultrasonic breath actuated respiratory droplet delivery device and methods of use |
US20200368483A1 (en) * | 2019-05-24 | 2020-11-26 | Stamford Devices Ltd. | Design of aerosol chamber and interface to optimize inhaled dose with neonatal cpap device |
CA3137298A1 (en) * | 2019-05-24 | 2020-12-03 | Stamford Devices Ltd. | Design of aerosol chamber and interface to optimize inhaled dose with neonatal cpap device |
EP4007626B1 (en) * | 2019-08-02 | 2023-09-13 | Stamford Devices Limited | Buccal administration of aerosol |
CN211132523U (en) * | 2019-08-23 | 2020-07-31 | 达尔生技股份有限公司 | Atomizer |
JP2022547826A (en) | 2019-08-27 | 2022-11-16 | トゥルーデル メディカル インターナショナル | Vibrating positive expiratory pressure device |
US11878115B2 (en) | 2019-09-26 | 2024-01-23 | Vapotherm, Inc. | Internal cannula mounted nebulizer |
USD985758S1 (en) | 2019-11-12 | 2023-05-09 | Hill-Rom Services Pte. Ltd. | End piece of a pneumatic patient circuit |
KR102364175B1 (en) | 2021-04-26 | 2022-02-18 | 엔텍메디칼(주) | Drug aerosol supply device for artificial respirator |
WO2022263049A1 (en) * | 2021-06-16 | 2022-12-22 | Stamford Devices Limited | A ventilator system |
KR20240037245A (en) | 2021-06-22 | 2024-03-21 | 뉴마 레스퍼러토리 인코포레이티드 | Droplet delivery device by push ejection |
CN113304363A (en) * | 2021-06-22 | 2021-08-27 | 南京宽诚科技有限公司 | Salt sol generating device |
KR20230130966A (en) | 2022-03-04 | 2023-09-12 | 바디텍메드(주) | Drug Aerosol Delivery Device for Ventilator |
WO2024047523A1 (en) * | 2022-08-30 | 2024-03-07 | Sia Emteko Holding | Inhalation device for administration of drugs by inhalation and inhalation system |
Family Cites Families (501)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US550315A (en) | 1895-11-26 | Frank napoleon allen | ||
US2735427A (en) * | 1956-02-21 | Hypodermic syringe | ||
US809159A (en) * | 1905-09-30 | 1906-01-02 | Richard M Willis | Dispensing bottle or jar. |
US1680616A (en) | 1922-06-06 | 1928-08-14 | Horst Friedrich Wilhelm | Sealed package |
US2022520A (en) | 1934-07-07 | 1935-11-26 | Parsons Ammonia Company Inc | Bottle |
US2101304A (en) | 1936-06-05 | 1937-12-07 | Sheaffer W A Pen Co | Fountain pen |
US2187528A (en) * | 1937-06-07 | 1940-01-16 | Russell T Wing | Fountain pen |
US2158615A (en) | 1937-07-26 | 1939-05-16 | Sheaffer W A Pen Co | Fountain pen |
US2266706A (en) | 1938-08-06 | 1941-12-16 | Stanley L Fox | Nasal atomizing inhaler and dropper |
NL62585C (en) | 1939-01-06 | |||
US2292381A (en) | 1940-12-24 | 1942-08-11 | Esterbrook Steel Pen Mfg Co | Fountain pen feed |
US2283333A (en) | 1941-05-22 | 1942-05-19 | Sheaffer W A Pen Co | Fountain pen |
US2383098A (en) | 1942-07-21 | 1945-08-21 | Jr Frank H Wheaton | Double-mouthed bottle |
US2375770A (en) | 1943-11-19 | 1945-05-15 | Arthur O Dahiberg | Fountain pen |
US2430023A (en) | 1944-01-27 | 1947-11-04 | Esterbrook Pen Co | Writing implement |
BE461043A (en) | 1944-04-10 | |||
US2404063A (en) | 1944-04-27 | 1946-07-16 | Parker Pen Co | Fountain pen |
US2521657A (en) | 1944-07-07 | 1950-09-05 | Scripto Inc | Fountain pen |
US2512004A (en) | 1945-03-05 | 1950-06-20 | Russell T Wing | Fountain pen |
US2474996A (en) | 1945-10-12 | 1949-07-05 | Sheaffer W A Pen Co | Fountain pen |
NL68028C (en) | 1946-06-08 | |||
US2693178A (en) * | 1949-12-21 | 1954-11-02 | Air Reduction | Demand type gas regulator |
US2705007A (en) * | 1951-09-10 | 1955-03-29 | Louis P Gerber | Inhaler |
US2764979A (en) | 1953-04-09 | 1956-10-02 | Henderson Edward | Medicament dispensing unit |
US2764946A (en) | 1954-04-05 | 1956-10-02 | Scognamillo Frank | Rotary pump |
US2779623A (en) * | 1954-09-10 | 1957-01-29 | Bernard J Eisenkraft | Electromechanical atomizer |
US2935970A (en) | 1955-03-23 | 1960-05-10 | Sapphire Products Inc | Fountain pen ink reservoir |
US3083707A (en) | 1956-02-13 | 1963-04-02 | Henry W Seeler | Device for treatment of pulmonary diseases |
DE1103522B (en) | 1957-10-24 | 1961-03-30 | Transform Roentgen Matern Veb | Exhalation device for aerosols generated by means of ultrasound |
US3066669A (en) | 1959-06-08 | 1962-12-04 | Melfy Frank A De | Nebulizer |
US3103310A (en) | 1961-11-09 | 1963-09-10 | Exxon Research Engineering Co | Sonic atomizer for liquids |
GB973458A (en) | 1962-10-16 | 1964-10-28 | Exxon Research Engineering Co | Improvements in or relating to methods and apparatus for atomising liquids |
US3247849A (en) | 1963-03-28 | 1966-04-26 | Calmar Inc | Pump-type sprayer for liquids having a dual-purpose protective cap for pump sealing and directional spray control |
FR1449600A (en) | 1964-09-14 | 1966-05-06 | Fr Des Laboratoires Labaz Soc | Improvements to flexible material bottles, especially for medicinal products |
DE1461628A1 (en) | 1965-04-30 | 1969-03-27 | Montblanc Simplo Gmbh | Ink feed for fountain pen |
US3680954A (en) | 1965-04-30 | 1972-08-01 | Eastman Kodak Co | Electrography |
DE1575050A1 (en) | 1966-01-12 | 1972-04-13 | Misto Gen Equipment Co | Ultrasonic fog generator |
DE1654994A1 (en) | 1967-02-17 | 1970-03-26 | Neff Werke Carl Neff Gmbh Bret | Floor-free cooking appliances, especially for large kitchens |
US3530856A (en) | 1967-02-28 | 1970-09-29 | Bird F M | Mechanical volume limiting ventilator |
US3550864A (en) | 1967-12-11 | 1970-12-29 | Borg Warner | High efficiency flashing nozzle |
US3561444A (en) * | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
US3515348A (en) | 1968-07-22 | 1970-06-02 | Lewbill Ind Inc | Mist-producing device |
US3558052A (en) * | 1968-10-31 | 1971-01-26 | F I N D Inc | Method and apparatus for spraying electrostatic dry powder |
US3563415A (en) * | 1969-06-04 | 1971-02-16 | Multi Drop Adapter Corp | Multidrop adapter |
US3719328A (en) * | 1970-10-22 | 1973-03-06 | C Hindman | Adjustable spray head |
CA930005A (en) | 1971-06-15 | 1973-07-10 | Siemens Aktiengesellschaft | Piezoelectric vibrators |
NO134730L (en) | 1971-07-19 | 1900-01-01 | ||
US3838686A (en) | 1971-10-14 | 1974-10-01 | G Szekely | Aerosol apparatus for inhalation therapy |
US3983740A (en) | 1971-12-07 | 1976-10-05 | Societe Grenobloise D'etudes Et D'applications Hydrauliques (Sogreah) | Method and apparatus for forming a stream of identical drops at very high speed |
US3790079A (en) * | 1972-06-05 | 1974-02-05 | Rnb Ass Inc | Method and apparatus for generating monodisperse aerosol |
US3778786A (en) | 1972-06-28 | 1973-12-11 | Nasa | Data storage, image tube type |
US3812854A (en) | 1972-10-20 | 1974-05-28 | A Michaels | Ultrasonic nebulizer |
US3842833A (en) | 1972-12-11 | 1974-10-22 | Ims Ltd | Neb-u-pack |
US3858739A (en) | 1973-03-05 | 1975-01-07 | Barnes Hind Diagnostics Inc | Breakaway neck container with integral cap |
FR2224175B1 (en) | 1973-04-04 | 1978-04-14 | Isf Spa | |
AT323114B (en) | 1973-05-07 | 1975-06-25 | Voest Ag | PROCEDURE FOR PRILLING |
US3804329A (en) * | 1973-07-27 | 1974-04-16 | J Martner | Ultrasonic generator and atomizer apparatus and method |
US3903884A (en) | 1973-08-15 | 1975-09-09 | Becton Dickinson Co | Manifold nebulizer system |
DE2361781A1 (en) * | 1973-12-12 | 1975-06-19 | Philips Patentverwaltung | WRITING WORK FOR WRITING WITH LIQUID INK |
US3865106A (en) * | 1974-03-18 | 1975-02-11 | Bernard P Palush | Positive pressure breathing circuit |
US3951313A (en) * | 1974-06-05 | 1976-04-20 | Becton, Dickinson And Company | Reservoir with prepacked diluent |
US3993223A (en) | 1974-07-25 | 1976-11-23 | American Home Products Corporation | Dispensing container |
US3908654A (en) | 1974-08-02 | 1975-09-30 | Rit Rech Ind Therapeut | Dispensing package for a dry biological and a liquid diluent |
DE2445791C2 (en) | 1974-09-25 | 1984-04-19 | Siemens AG, 1000 Berlin und 8000 München | Ultrasonic liquid atomizer |
AR205589A1 (en) | 1974-10-09 | 1976-05-14 | Reckitt & Colmann Prod Ltd | INTRODUCING DEVICE OF AN AQUEOUS COMPOSITION INTO A BODY CAVITY |
US3958249A (en) | 1974-12-18 | 1976-05-18 | International Business Machines Corporation | Ink jet drop generator |
US4059384A (en) | 1975-01-20 | 1977-11-22 | Misto2 Gen Equipment Co. | Two-step injection molding |
AT337345B (en) | 1975-02-05 | 1977-06-27 | Draegerwerk Ag | BREATHING ASSISTANCE DEVICE AND / OR ARTIFICIAL VENTILATION DEVICE FOR HUMAN USE |
US4005435A (en) * | 1975-05-15 | 1977-01-25 | Burroughs Corporation | Liquid jet droplet generator |
US4020834A (en) | 1975-05-16 | 1977-05-03 | Bird F M | Respirator and method |
AU67278S (en) | 1975-06-04 | 1975-11-12 | Warner Lambert Co | Bottle |
DE2537765B2 (en) | 1975-08-25 | 1981-04-09 | Siemens AG, 1000 Berlin und 8000 München | Medical inhalation device for the treatment of diseases of the respiratory tract |
GB1571304A (en) | 1976-02-24 | 1980-07-16 | Lucas Industries Ltd | Drive circuit for a piezo electric crystal |
US4094317A (en) | 1976-06-11 | 1978-06-13 | Wasnich Richard D | Nebulization system |
US4121583A (en) | 1976-07-13 | 1978-10-24 | Wen Yuan Chen | Method and apparatus for alleviating asthma attacks |
US4076021A (en) * | 1976-07-28 | 1978-02-28 | Thompson Harris A | Positive pressure respiratory apparatus |
US4083368A (en) * | 1976-09-01 | 1978-04-11 | Freezer Winthrop J | Inhaler |
USD249958S (en) | 1977-01-10 | 1978-10-17 | Warner-Lambert Company | Dispensing container for pharmaceutical diluents |
US4163450A (en) * | 1977-01-27 | 1979-08-07 | Cramp Harvey E | Method and apparatus for weaning patient from continuous mechanical ventilation |
US4106503A (en) | 1977-03-11 | 1978-08-15 | Richard R. Rosenthal | Metering system for stimulating bronchial spasm |
US4159803A (en) | 1977-03-31 | 1979-07-03 | MistO2 Gen Equipment Company | Chamber for ultrasonic aerosol generation |
US4113809A (en) | 1977-04-04 | 1978-09-12 | Champion Spark Plug Company | Hand held ultrasonic nebulizer |
US4101041A (en) | 1977-08-01 | 1978-07-18 | Becton, Dickinson And Company | Prefillable, hermetically sealed container adapted for use with a humidifier or nebulizer head |
US4268460A (en) * | 1977-12-12 | 1981-05-19 | Warner-Lambert Company | Nebulizer |
USD259213S (en) | 1978-03-13 | 1981-05-12 | Automatic Liquid Packaging, Inc. | Vial suitable for pharmaceuticals |
DE2811248C3 (en) | 1978-03-15 | 1981-11-26 | Bosch-Siemens Hausgeräte GmbH, 7000 Stuttgart | Liquid atomizer |
US4298045A (en) | 1978-04-17 | 1981-11-03 | Automatic Liquid Packaging, Inc. | Dispensing container with plural removable closure means unitary therewith |
US4338576A (en) | 1978-07-26 | 1982-07-06 | Tdk Electronics Co., Ltd. | Ultrasonic atomizer unit utilizing shielded and grounded elements |
US4210155A (en) | 1978-08-03 | 1980-07-01 | Jerry Grimes | Inspirational inhalation spirometer apparatus |
DE2843756B2 (en) | 1978-10-06 | 1981-07-09 | Hense GmbH & Co, 4930 Detmold | Device for generating an aerosol |
US4240081A (en) | 1978-10-13 | 1980-12-16 | Dennison Manufacturing Company | Ink jet printing |
DE2849493C2 (en) | 1978-11-15 | 1982-01-14 | Carl Heyer Gmbh, Inhalationstechnik, 5427 Bad Ems | Hand-held aerosol dispenser |
DE2854841C2 (en) | 1978-12-19 | 1981-03-26 | Bosch-Siemens Hausgeräte GmbH, 7000 Stuttgart | Liquid atomizer, preferably inhalation device |
JPS5848225B2 (en) * | 1979-01-09 | 1983-10-27 | オムロン株式会社 | Atomization amount control method of ultrasonic liquid atomization device |
DE2907348A1 (en) * | 1979-02-24 | 1980-09-04 | Boehringer Sohn Ingelheim | IMPROVED INHALATION DEVICES |
US4207990A (en) | 1979-05-03 | 1980-06-17 | Automatic Liquid Packaging, Inc. | Hermetically sealed container with plural access ports |
US4226236A (en) | 1979-05-07 | 1980-10-07 | Abbott Laboratories | Prefilled, vented two-compartment syringe |
US4248227A (en) * | 1979-05-14 | 1981-02-03 | Bristol-Myers Company | Fluid unit dispensing device |
US4240417A (en) | 1979-06-13 | 1980-12-23 | Holever Bernard K | Tracheal tube adapter for ventilating apparatus |
DE7917568U1 (en) | 1979-06-19 | 1979-09-20 | Bosch-Siemens Hausgeraete Gmbh, 7000 Stuttgart | INHALATION DEVICE |
JPS5689569A (en) * | 1979-12-19 | 1981-07-20 | Canon Inc | Ink jet recording head |
US4291838A (en) | 1979-12-26 | 1981-09-29 | C. R. Bard, Inc. | Nebulizer and associated heater |
US4368850A (en) * | 1980-01-17 | 1983-01-18 | George Szekely | Dry aerosol generator |
DE3010178C2 (en) * | 1980-03-17 | 1985-10-03 | Kraftwerk Union AG, 4330 Mülheim | Slotted nozzle equipped with a quick-acting valve to induce pulsed gas flows |
NL189237C (en) | 1980-04-12 | 1993-02-16 | Battelle Institut E V | DEVICE FOR SPRAYING LIQUIDS. |
US4336544A (en) | 1980-08-18 | 1982-06-22 | Hewlett-Packard Company | Method and apparatus for drop-on-demand ink jet printing |
JPS5929118B2 (en) * | 1980-09-19 | 1984-07-18 | セイコーエプソン株式会社 | Palladium/nickel alloy plating liquid |
US4465234A (en) | 1980-10-06 | 1984-08-14 | Matsushita Electric Industrial Co., Ltd. | Liquid atomizer including vibrator |
US4389071A (en) | 1980-12-12 | 1983-06-21 | Hydronautics, Inc. | Enhancing liquid jet erosion |
US4474251A (en) | 1980-12-12 | 1984-10-02 | Hydronautics, Incorporated | Enhancing liquid jet erosion |
US4374707A (en) * | 1981-03-19 | 1983-02-22 | Xerox Corporation | Orifice plate for ink jet printing machines |
US5862802A (en) * | 1981-04-03 | 1999-01-26 | Forrest M. Bird | Ventilator having an oscillatory inspiratory phase and method |
US4454877A (en) | 1981-05-26 | 1984-06-19 | Andrew Boettner | Portable nebulizer or mist producing device |
FR2507087B1 (en) | 1981-06-06 | 1986-06-27 | Rowenta Werke Gmbh | ULTRASONIC INHALER |
US4408719A (en) | 1981-06-17 | 1983-10-11 | Last Anthony J | Sonic liquid atomizer |
US4475113A (en) | 1981-06-18 | 1984-10-02 | International Business Machines | Drop-on-demand method and apparatus using converging nozzles and high viscosity fluids |
JPS5861857A (en) | 1981-10-09 | 1983-04-13 | Matsushita Electric Works Ltd | Liquid atomizer |
AU553251B2 (en) | 1981-10-15 | 1986-07-10 | Matsushita Electric Industrial Co., Ltd. | Arrangement for ejecting liquid |
US4474326A (en) | 1981-11-24 | 1984-10-02 | Tdk Electronics Co., Ltd. | Ultrasonic atomizing device |
JPS58119108A (en) * | 1982-01-09 | 1983-07-15 | 森 敬 | Decoration lamp |
CA1206996A (en) | 1982-01-18 | 1986-07-02 | Naoyoshi Maehara | Ultrasonic liquid ejecting apparatus |
US5073484A (en) | 1982-03-09 | 1991-12-17 | Bio-Metric Systems, Inc. | Quantitative analysis apparatus and method |
US4470412A (en) | 1982-03-19 | 1984-09-11 | Trutek Research, Inc. | Inhalation valve |
DE3311956A1 (en) | 1982-03-31 | 1983-10-13 | Ricoh Co., Ltd., Tokyo | COLOR JET PRINTER HEAD |
US4823784A (en) | 1982-04-30 | 1989-04-25 | Cadema Medical Products, Inc. | Aerosol inhalation apparatus |
US4566452A (en) * | 1982-07-12 | 1986-01-28 | American Hospital Supply Corporation | Nebulizer |
JPS5912775A (en) | 1982-07-14 | 1984-01-23 | Matsushita Electric Ind Co Ltd | Atomizing pump unit |
DE3229921A1 (en) | 1982-08-11 | 1984-02-16 | Linde Ag, 6200 Wiesbaden | METHOD FOR THE SIMULTANEOUS FILLING OF SEVERAL ACETYLENE-FILLED BOTTLES OF SOLVENTS |
US5512329A (en) | 1982-09-29 | 1996-04-30 | Bsi Corporation | Substrate surface preparation |
US4722906A (en) * | 1982-09-29 | 1988-02-02 | Bio-Metric Systems, Inc. | Binding reagents and methods |
US4973493A (en) | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
US5002582A (en) * | 1982-09-29 | 1991-03-26 | Bio-Metric Systems, Inc. | Preparation of polymeric surfaces via covalently attaching polymers |
US5217492A (en) | 1982-09-29 | 1993-06-08 | Bio-Metric Systems, Inc. | Biomolecule attachment to hydrophobic surfaces |
US5258041A (en) | 1982-09-29 | 1993-11-02 | Bio-Metric Systems, Inc. | Method of biomolecule attachment to hydrophobic surfaces |
IT1156090B (en) | 1982-10-26 | 1987-01-28 | Olivetti & Co Spa | INK JET PRINTING METHOD AND DEVICE |
US4512341A (en) * | 1982-11-22 | 1985-04-23 | Lester Victor E | Nebulizer with capillary feed |
US4632311A (en) | 1982-12-20 | 1986-12-30 | Matsushita Electric Industrial Co., Ltd. | Atomizing apparatus employing a capacitive piezoelectric transducer |
DE3320441A1 (en) | 1983-06-06 | 1984-12-06 | Siemens AG, 1000 Berlin und 8000 München | WRITING DEVICE WORKING WITH LIQUID DROPLETS WITH ROD-SHAPED PIEZOELECTRIC TRANSFORMERS CONNECTED ON BOTH ENDS WITH A NOZZLE PLATE |
EP0134847B1 (en) | 1983-08-02 | 1987-05-27 | Trutek Research Inc. | Inhalation valve |
US4544933A (en) | 1983-09-20 | 1985-10-01 | Siemens Aktiengesellschaft | Apparatus and method for ink droplet ejection for a printer |
EP0156409A3 (en) | 1984-02-23 | 1986-06-25 | Jean Michel Anthony | Device for moistening parts of the human body |
US4593291A (en) | 1984-04-16 | 1986-06-03 | Exxon Research And Engineering Co. | Method for operating an ink jet device to obtain high resolution printing |
DE3574344D1 (en) | 1984-08-29 | 1989-12-28 | Omron Tateisi Electronics Co | Ultrasonic atomizer |
US4628890A (en) | 1984-08-31 | 1986-12-16 | Freeman Winifer W | Fuel atomizer |
DE3582287D1 (en) | 1984-09-07 | 1991-05-02 | Omron Tateisi Electronics Co | VIBRATION GENERATOR FOR AN INHALATION DEVICE WITH ULTRASONIC SPRAYING. |
US4826759A (en) | 1984-10-04 | 1989-05-02 | Bio-Metric Systems, Inc. | Field assay for ligands |
NZ209900A (en) | 1984-10-16 | 1989-08-29 | Univ Auckland | Automatic inhaler |
US4550325A (en) | 1984-12-26 | 1985-10-29 | Polaroid Corporation | Drop dispensing device |
DE3500985A1 (en) | 1985-01-14 | 1986-07-17 | Siemens AG, 1000 Berlin und 8000 München | ARRANGEMENT FOR PRODUCING SINGLE DROPLES IN INK WRITING DEVICES |
SE447318B (en) | 1985-05-21 | 1986-11-03 | Nils Goran Stemme | INTEGRATED SEMICONDUCTOR CIRCUIT WITH JOINT OF THERMALLY INSULATING SUBJECT, SET TO MAKE CIRCUIT AND ITS USE IN A FLOOD METER |
DE3523947A1 (en) | 1985-07-04 | 1987-01-08 | Draegerwerk Ag | NARCOSIS EVAPORATOR WITH INTERCHANGEABLE EVAPORATOR CHAMBER |
DE3524701A1 (en) | 1985-07-11 | 1987-01-15 | Bosch Gmbh Robert | ULTRASONIC SPRAYER NOZZLE |
US4613326A (en) | 1985-07-12 | 1986-09-23 | Becton, Dickinson And Company | Two-component medication syringe assembly |
US4659014A (en) | 1985-09-05 | 1987-04-21 | Delavan Corporation | Ultrasonic spray nozzle and method |
US4702418A (en) | 1985-09-09 | 1987-10-27 | Piezo Electric Products, Inc. | Aerosol dispenser |
ES2042184T3 (en) | 1985-12-02 | 1993-12-01 | Marco Alfredo Ganser | DEVICE FOR CONTROLLING ELECTRO-HYDRAULIC FUEL INJECTORS. |
US4753579A (en) | 1986-01-22 | 1988-06-28 | Piezo Electric Products, Inc. | Ultrasonic resonant device |
US4678680A (en) | 1986-02-20 | 1987-07-07 | Xerox Corporation | Corrosion resistant aperture plate for ink jet printers |
JPS62221352A (en) | 1986-03-22 | 1987-09-29 | 株式会社新素材総合研究所 | Liquid drug containing container preventing deterioratioan of liquid drug by oxygen and its production |
SE8601351D0 (en) | 1986-03-24 | 1986-03-24 | Nilsson Sven Erik | MANAGED ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE SUBJECTS |
US4658269A (en) * | 1986-06-02 | 1987-04-14 | Xerox Corporation | Ink jet printer with integral electrohydrodynamic electrodes and nozzle plate |
US4849303A (en) | 1986-07-01 | 1989-07-18 | E. I. Du Pont De Nemours And Company | Alloy coatings for electrical contacts |
US4799622A (en) * | 1986-08-05 | 1989-01-24 | Tao Nenryo Kogyo Kabushiki Kaisha | Ultrasonic atomizing apparatus |
DE3627222A1 (en) | 1986-08-11 | 1988-02-18 | Siemens Ag | ULTRASONIC POCKET SPRAYER |
US4819834A (en) | 1986-09-09 | 1989-04-11 | Minnesota Mining And Manufacturing Company | Apparatus and methods for delivering a predetermined amount of a pressurized fluid |
US4871489A (en) | 1986-10-07 | 1989-10-03 | Corning Incorporated | Spherical particles having narrow size distribution made by ultrasonic vibration |
US5263992A (en) | 1986-10-17 | 1993-11-23 | Bio-Metric Systems, Inc. | Biocompatible device with covalently bonded biocompatible agent |
US4979959A (en) | 1986-10-17 | 1990-12-25 | Bio-Metric Systems, Inc. | Biocompatible coating for solid surfaces |
DE3636669C2 (en) | 1986-10-28 | 2001-08-16 | Siemens Ag | Arrangement for delivering aerosol to a patient's airways and / or lungs |
DE3637631C1 (en) | 1986-11-05 | 1987-08-20 | Philips Patentverwaltung | Process for applying small amounts of molten, drop-shaped solder from a nozzle to surfaces to be wetted and device for carrying out the process |
US4976259A (en) | 1986-12-22 | 1990-12-11 | Mountain Medical Equipment, Inc. | Ultrasonic nebulizer |
DE3760650D1 (en) * | 1987-03-17 | 1989-11-09 | Lechler Gmbh & Co Kg | Ultrasonic liquid sprayer |
JPS63230957A (en) | 1987-03-20 | 1988-09-27 | Hitachi Ltd | Liquid atomizing device |
US4850534A (en) | 1987-05-30 | 1989-07-25 | Tdk Corporation | Ultrasonic wave nebulizer |
EP0295337B1 (en) * | 1987-06-16 | 1991-12-04 | Akzo Nobel N.V. | Two compartment syringe and method of manufacturing |
US5199424A (en) | 1987-06-26 | 1993-04-06 | Sullivan Colin E | Device for monitoring breathing during sleep and control of CPAP treatment that is patient controlled |
US5522382A (en) * | 1987-06-26 | 1996-06-04 | Rescare Limited | Device and method for treating obstructed breathing having a delay/ramp feature |
IL86799A (en) | 1987-07-02 | 1993-03-15 | Kabi Pharmacia Ab | Method and device for injection |
US5080093A (en) * | 1987-07-08 | 1992-01-14 | Vortran Medical Technology, Inc. | Intermittant signal actuated nebulizer |
US5322057A (en) | 1987-07-08 | 1994-06-21 | Vortran Medical Technology, Inc. | Intermittent signal actuated nebulizer synchronized to operate in the exhalation phase, and its method of use |
US4805609A (en) * | 1987-07-17 | 1989-02-21 | Josephine A. Roberts | Pressurized ventilation system for patients |
US5388571A (en) * | 1987-07-17 | 1995-02-14 | Roberts; Josephine A. | Positive-pressure ventilator system with controlled access for nebulizer component servicing |
DE3724629A1 (en) | 1987-07-22 | 1989-02-02 | Siemens Ag | PIEZOELECTRICALLY REQUIRED RESONANCE SYSTEM |
US5139016A (en) | 1987-08-07 | 1992-08-18 | Sorin Biomedica S.P.A. | Process and device for aerosol generation for pulmonary ventilation scintigraphy |
FR2622113A1 (en) * | 1987-10-27 | 1989-04-28 | Medipro | Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation |
FR2624017A1 (en) * | 1987-12-03 | 1989-06-09 | Medipro | Medicament comprising a combination of colistin, amikacin and amphotericin B administered by vaporisation |
FI82808C (en) | 1987-12-31 | 1991-04-25 | Etelae Haemeen Keuhkovammayhdi | Ultraljudfinfördelningsanordning |
DE3808308A1 (en) | 1988-03-12 | 1989-09-21 | Merck Patent Gmbh | OPENING AID FOR AMPOULES |
US5115971A (en) | 1988-09-23 | 1992-05-26 | Battelle Memorial Institute | Nebulizer device |
NL8801260A (en) | 1988-05-16 | 1989-12-18 | Mobacc Bv | NOZZLE FOR A SPRAY CAN. |
DE3818682A1 (en) | 1988-06-01 | 1989-12-21 | Deussen Stella Kg | AMPOULE |
US5201322A (en) | 1988-08-17 | 1993-04-13 | Elf Atochem North America, Inc. | Device for detecting air flow through a passageway |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
DE3916840A1 (en) | 1988-09-21 | 1990-03-29 | Bernd Hansen | Ampoule with specified shape of neck - for passage of air but not liq. when syringe neck is inserted for extn. |
US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
US5021701A (en) | 1988-10-20 | 1991-06-04 | Tdk Corporation | Piezoelectric vibrator mounting system for a nebulizer |
USD312209S (en) | 1988-10-21 | 1990-11-20 | Becton, Dickinson And Company | Dispensing vial or the like |
EP0373237A1 (en) | 1988-12-13 | 1990-06-20 | Siemens Aktiengesellschaft | Pocket inhaler device |
SE466684B (en) | 1989-03-07 | 1992-03-23 | Draco Ab | DEVICE INHALATOR AND PROCEDURE TO REGISTER WITH THE DEVICE INHALATOR MEDICATION |
JPH02269058A (en) | 1989-03-14 | 1990-11-02 | Seiko Epson Corp | Liquid drop jet device by use of rayleigh mode surface acoustic wave |
WO1990012655A1 (en) | 1989-04-14 | 1990-11-01 | Azerbaidzhansky Politekhnichesky Institut Imeni Ch.Ildryma | Device for ultrasonic dispersion of a liquid medium |
US5022587A (en) | 1989-06-07 | 1991-06-11 | Hochstein Peter A | Battery powered nebulizer |
US5086785A (en) * | 1989-08-10 | 1992-02-11 | Abrams/Gentille Entertainment Inc. | Angular displacement sensors |
US5562608A (en) | 1989-08-28 | 1996-10-08 | Biopulmonics, Inc. | Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation |
US5024733A (en) | 1989-08-29 | 1991-06-18 | At&T Bell Laboratories | Palladium alloy electroplating process |
US5007419A (en) | 1989-09-25 | 1991-04-16 | Allan Weinstein | Inhaler device |
US5227168A (en) | 1989-11-21 | 1993-07-13 | Bruce Barber | Method of treating a wound |
US5002048A (en) * | 1989-12-12 | 1991-03-26 | Makiej Jr Walter J | Inhalation device utilizing two or more aerosol containers |
US5152456A (en) | 1989-12-12 | 1992-10-06 | Bespak, Plc | Dispensing apparatus having a perforate outlet member and a vibrating device |
CH680546A5 (en) | 1989-12-15 | 1992-09-15 | Klaus Weigelt Dr Ing | |
US4971665A (en) | 1989-12-18 | 1990-11-20 | Eastman Kodak Company | Method of fabricating orifice plates with reusable mandrel |
US5016024A (en) | 1990-01-09 | 1991-05-14 | Hewlett-Packard Company | Integral ink jet print head |
US4954225A (en) | 1990-01-10 | 1990-09-04 | Dynamics Research Corporation | Method for making nozzle plates |
DK0440846T3 (en) * | 1990-02-07 | 1993-07-12 | Vetter & Co Apotheker | Double chamber syringe and application method |
SG45171A1 (en) * | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
US5122116A (en) | 1990-04-24 | 1992-06-16 | Science Incorporated | Closed drug delivery system |
FR2662672B1 (en) | 1990-05-31 | 1992-08-21 | Aerosols & Bouchage | MIXTURE DISPENSER. |
GB9015077D0 (en) | 1990-07-09 | 1990-08-29 | Riker Laboratories Inc | Inhaler |
US5309135A (en) | 1990-07-13 | 1994-05-03 | Langford Gordon B | Flexible potentiometer in a horn control system |
US5157372A (en) | 1990-07-13 | 1992-10-20 | Langford Gordon B | Flexible potentiometer |
FR2665849B1 (en) * | 1990-08-20 | 1995-03-24 | Dynamad | ULTRASONIC DEVICE FOR THE CONTINUOUS PRODUCTION OF PARTICLES. |
US5086765A (en) * | 1990-08-29 | 1992-02-11 | Walter Levine | Nebulizer |
USD327008S (en) | 1990-08-29 | 1992-06-16 | True Products Sampling, Inc. | Cosmetic sample container |
US5115803A (en) | 1990-08-31 | 1992-05-26 | Minnesota Mining And Manufacturing Company | Aerosol actuator providing increased respirable fraction |
GB9020555D0 (en) | 1990-09-20 | 1990-10-31 | Bespak Plc | Dispensing apparatus |
US5304125A (en) | 1990-10-05 | 1994-04-19 | The University Of North Carolina | Apparatus for administering solid particulate aerosols to the lungs |
DE69117127T2 (en) | 1990-10-11 | 1996-11-07 | Toda Koji | Ultrasonic atomizer |
CA2027690A1 (en) | 1990-10-18 | 1992-04-19 | Christian Laing | Plastic ampul |
GB9023281D0 (en) | 1990-10-25 | 1990-12-05 | Riker Laboratories Inc | Inhaler |
US5129579A (en) | 1990-10-25 | 1992-07-14 | Sun Microsystems, Inc. | Vacuum attachment for electronic flux nozzle |
US5487378A (en) * | 1990-12-17 | 1996-01-30 | Minnesota Mining And Manufacturing Company | Inhaler |
US6006745A (en) | 1990-12-21 | 1999-12-28 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
US5062419A (en) | 1991-01-07 | 1991-11-05 | Rider Donald L | Nebulizer with valved "T" assembly |
US5217148A (en) | 1991-02-11 | 1993-06-08 | Spruhventile Gmbh | Pharmaceutical pump dispenser |
US5147073A (en) | 1991-02-11 | 1992-09-15 | Spruhventile Gmbh | Fluid pump dispenser for pharmaceutical use |
US5099833A (en) | 1991-02-19 | 1992-03-31 | Baxter International Inc. | High efficiency nebulizer having a flexible reservoir |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5392768A (en) | 1991-03-05 | 1995-02-28 | Aradigm | Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval |
DE69430303T2 (en) | 1991-03-05 | 2002-11-28 | Aradigm Corp | METHOD AND DEVICE FOR CORRECTING A ZERO SIGNAL OF A PRESSURE SENSOR FOR A FLOW METER |
US5186164A (en) * | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
WO1992017231A1 (en) | 1991-03-28 | 1992-10-15 | Innomed, Inc. | Microelectronic inhaler having a counter and timer |
US5348189A (en) | 1991-04-10 | 1994-09-20 | Bespak Plc | Air purge pump dispenser |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US6540154B1 (en) * | 1991-04-24 | 2003-04-01 | Aerogen, Inc. | Systems and methods for controlling fluid feed to an aerosol generator |
US5164740A (en) | 1991-04-24 | 1992-11-17 | Yehuda Ivri | High frequency printing mechanism |
US5938117A (en) | 1991-04-24 | 1999-08-17 | Aerogen, Inc. | Methods and apparatus for dispensing liquids as an atomized spray |
US6629646B1 (en) | 1991-04-24 | 2003-10-07 | Aerogen, Inc. | Droplet ejector with oscillating tapered aperture |
US5241954A (en) | 1991-05-24 | 1993-09-07 | Glenn Joseph G | Nebulizer |
DE69210096T2 (en) | 1991-05-27 | 1996-09-19 | Tdk Corp | Ultrasonic atomizer |
JPH0614756Y2 (en) | 1991-06-26 | 1994-04-20 | 株式会社アルテ | Assembled dual chamber syringe |
ES2284226T3 (en) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | DEVICE FOR PROVIDING MEDICATIONS IN AEROSOL. |
WO1993001404A1 (en) | 1991-07-08 | 1993-01-21 | Yehuda Ivri | Ultrasonic fluid ejector |
DE4124032A1 (en) | 1991-07-19 | 1993-01-21 | Bosch Gmbh Robert | MEASURING ELEMENT |
US5180482A (en) * | 1991-07-22 | 1993-01-19 | At&T Bell Laboratories | Thermal annealing of palladium alloys |
US5230496A (en) | 1991-08-06 | 1993-07-27 | Med-Safe Systems, Inc. | Pole mounting clamp |
US5601077A (en) * | 1991-08-07 | 1997-02-11 | Becton, Dickinson And Company | Nasal syringe sprayer with removable dose limiting structure |
DE4127650C1 (en) | 1991-08-21 | 1993-02-25 | Arzneimittel Gmbh Apotheker Vetter & Co Ravensburg, 7980 Ravensburg, De | |
PL169046B1 (en) | 1991-08-29 | 1996-05-31 | Christoph Klein | Medical instrument for aerosol inhalation |
US5170782A (en) | 1991-09-12 | 1992-12-15 | Devilbiss Health Care, Inc. | Medicament nebulizer with improved aerosol chamber |
US5291838A (en) | 1991-10-10 | 1994-03-08 | Tandem Computers Incorporated | Packaging system |
DK0540775T3 (en) | 1991-11-07 | 1997-08-25 | Ritzau Pari Werk Gmbh Paul | Especially for use in inhalation therapy apparatus |
US5518179A (en) | 1991-12-04 | 1996-05-21 | The Technology Partnership Limited | Fluid droplets production apparatus and method |
DE69218901T2 (en) | 1991-12-10 | 1997-07-17 | Tdk Corp | Ultrasonic atomizer |
EP0585436B1 (en) | 1992-02-13 | 2000-05-03 | SurModics, Inc. | Immobilization of chemical species in crosslinked matrices |
US5186166A (en) * | 1992-03-04 | 1993-02-16 | Riggs John H | Powder nebulizer apparatus and method of nebulization |
US5355872B1 (en) | 1992-03-04 | 1998-10-20 | John H Riggs | Low flow rate nebulizer apparatus and method of nebulization |
JPH05271980A (en) | 1992-03-30 | 1993-10-19 | Yazaki Corp | Palladium-nickel alloy plating liquid |
EP0933138B1 (en) | 1992-04-09 | 2004-03-03 | Omron Healthcare Co., Ltd. | Ultrasonic atomizer |
DE69333443T2 (en) | 1992-04-09 | 2005-03-24 | Omron Healthcare Co., Ltd. | ultrasonic nebulizer |
GB9207940D0 (en) | 1992-04-10 | 1992-05-27 | Alcan Int Ltd | Motors |
US5248087A (en) | 1992-05-08 | 1993-09-28 | Dressler John L | Liquid droplet generator |
US5512474A (en) | 1992-05-29 | 1996-04-30 | Bsi Corporation | Cell culture support containing a cell adhesion factor and a positively-charged molecule |
US5431155A (en) | 1992-06-03 | 1995-07-11 | Elettro Plastica S.P.A. | Single-dose nasal dispenser for atomized liquid drugs |
FR2692569B1 (en) | 1992-06-18 | 1996-08-30 | Valois | METHOD AND DEVICE FOR FILLING A FLUID SUBSTANCE METER DISPENSER. |
FR2693910B1 (en) * | 1992-07-23 | 1994-08-26 | Taema | Equipment and methods for delivering doses of at least one gas to the respiratory tract of a user. |
US5287849A (en) * | 1992-07-24 | 1994-02-22 | Vortran Medical Technology, Inc. | Medicinal aerosol delivery system and method of use |
JP3178945B2 (en) | 1992-08-25 | 2001-06-25 | 日本碍子株式会社 | Inkjet print head |
DE4230645C2 (en) | 1992-09-12 | 1996-03-07 | Bernd Hansen | ampoule |
US5372126A (en) | 1992-09-14 | 1994-12-13 | Blau; Anthony D. | Pulmonary sampling chamber |
US5392769A (en) * | 1992-10-06 | 1995-02-28 | Vinatroics Division | One-way valve |
US5357946A (en) | 1992-10-19 | 1994-10-25 | Sherwood Medical Company | Ventilator manifold with accessory access port and adaptors therefore |
US5445141A (en) | 1992-10-19 | 1995-08-29 | Sherwood Medical Company | Respiratory support system |
DK167300B1 (en) | 1992-10-27 | 1993-10-11 | Samka Vejle As | MACHINERY AND PROCEDURES FOR SEALING AND COATING POTATOES |
ATE156312T1 (en) | 1992-10-27 | 1997-08-15 | Canon Kk | METHOD FOR PUMPING LIQUIDS |
US5313955A (en) | 1992-10-30 | 1994-05-24 | Rodder Jerome A | Pulmonary flow head |
GB2272389B (en) | 1992-11-04 | 1996-07-24 | Bespak Plc | Dispensing apparatus |
US5414075A (en) | 1992-11-06 | 1995-05-09 | Bsi Corporation | Restrained multifunctional reagent for surface modification |
US5346132A (en) | 1992-11-12 | 1994-09-13 | Gary S. Hahn | Mist generator |
US5378231A (en) * | 1992-11-25 | 1995-01-03 | Abbott Laboratories | Automated drug infusion system |
GB9225098D0 (en) | 1992-12-01 | 1993-01-20 | Coffee Ronald A | Charged droplet spray mixer |
US5452711A (en) | 1992-12-24 | 1995-09-26 | Exar Corporation | Small form factor atomizer |
US5449502A (en) | 1992-12-30 | 1995-09-12 | Sanden Corp. | Sterilizing apparatus utilizing ultrasonic vibration |
US5342011A (en) | 1993-01-19 | 1994-08-30 | Sherwood Medical Company | Fluid container attachment adaptor for an ambulatory fluid delivery system |
JPH08509465A (en) | 1993-01-29 | 1996-10-08 | マイリス メディカル コーポレーション | Intrapulmonary delivery of hormones |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US5724957A (en) * | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US6012450A (en) * | 1993-01-29 | 2000-01-11 | Aradigm Corporation | Intrapulmonary delivery of hematopoietic drug |
US5350116A (en) | 1993-03-01 | 1994-09-27 | Bespak Plc | Dispensing apparatus |
US5458289A (en) | 1993-03-01 | 1995-10-17 | Bespak Plc | Liquid dispensing apparatus with reduced clogging |
US5303854A (en) | 1993-03-08 | 1994-04-19 | Spruhventile Gmbh | Pharmaceutical pump dispenser having hydraulically closed outlet port |
US5279568A (en) * | 1993-04-30 | 1994-01-18 | Spruhventile Gmbh | Pharmaceutical pump dispenser for fluid suspensions and fluid mixtures |
GB9305975D0 (en) | 1993-03-23 | 1993-05-12 | Minnesota Mining & Mfg | Metered-dose aerosol valves |
US5383906A (en) * | 1993-05-12 | 1995-01-24 | Burchett; Mark T. | Nursing bottle with medication dispenser |
US5396883A (en) * | 1993-05-18 | 1995-03-14 | Knupp; Jacob E. | Nebulizer valve assembly for use in a ventilation circuit |
US5497763A (en) * | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
US5709202A (en) * | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
FR2705911B1 (en) | 1993-06-02 | 1995-08-11 | Oreal | Piezoelectric nebulization device. |
GB9311892D0 (en) | 1993-06-09 | 1993-07-28 | Glaxo Wellcome Australia Ltd | Device |
GB2279571A (en) | 1993-06-14 | 1995-01-11 | Minnesota Mining & Mfg | Inhaler |
GB9312984D0 (en) | 1993-06-23 | 1993-08-04 | Bespak Plc | Atomising dispenser |
ES2171455T3 (en) | 1993-06-29 | 2002-09-16 | Ponwell Entpr Ltd | DISPENSER. |
US5437267A (en) | 1993-08-03 | 1995-08-01 | Weinstein; Allan | Device for delivering aerosol to the nasal membranes and method of use |
US5426458A (en) | 1993-08-09 | 1995-06-20 | Hewlett-Packard Corporation | Poly-p-xylylene films as an orifice plate coating |
CH686872A5 (en) | 1993-08-09 | 1996-07-31 | Disetronic Ag | Medical Inhalationsgeraet. |
US5485850A (en) * | 1993-08-13 | 1996-01-23 | Dietz; Henry G. | Monitor of low pressure intervals with control capabilities |
US5918637A (en) | 1993-08-16 | 1999-07-06 | Fleischman; William H. | Plates perforated with venturi-like orifices |
US5415161A (en) * | 1993-09-15 | 1995-05-16 | Ryder; Steven L. | Intermittant demand aerosol control device |
US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
GB9324250D0 (en) | 1993-11-25 | 1994-01-12 | Minnesota Mining & Mfg | Inhaler |
GB9412669D0 (en) | 1994-06-23 | 1994-08-10 | The Technology Partnership Plc | Liquid spray apparatus |
US5570682A (en) | 1993-12-14 | 1996-11-05 | Ethex International, Inc. | Passive inspiratory nebulizer system |
US5752502A (en) | 1993-12-16 | 1998-05-19 | King; Russell Wayne | General purpose aerosol inhalation apparatus |
US5489266A (en) * | 1994-01-25 | 1996-02-06 | Becton, Dickinson And Company | Syringe assembly and method for lyophilizing and reconstituting injectable medication |
US5632878A (en) | 1994-02-01 | 1997-05-27 | Fet Engineering, Inc. | Method for manufacturing an electroforming mold |
US5579757A (en) | 1994-02-02 | 1996-12-03 | Baxter International, Inc. | Anti-siphon flow restricter for a nebulizer |
US5479920A (en) * | 1994-03-01 | 1996-01-02 | Vortran Medical Technology, Inc. | Breath actuated medicinal aerosol delivery apparatus |
US5664557A (en) | 1994-03-10 | 1997-09-09 | Respiratory Delivery Systems, Inc. | Releasably engageable coupling for an inhaler |
USD375352S (en) | 1994-03-14 | 1996-11-05 | Columbia Laboratories, Inc. | Dispensing vial for feminine hygiene products |
US5435282A (en) | 1994-05-19 | 1995-07-25 | Habley Medical Technology Corporation | Nebulizer |
GB9410658D0 (en) | 1994-05-27 | 1994-07-13 | Electrosols Ltd | Dispensing device |
USD362390S (en) | 1994-06-02 | 1995-09-19 | Automatic Liquid Packaging, Inc. | Hermetically sealed vial |
US5482030A (en) | 1994-06-13 | 1996-01-09 | Klein; David | Aerosol and non-aerosol spray counter |
US5516043A (en) | 1994-06-30 | 1996-05-14 | Misonix Inc. | Ultrasonic atomizing device |
US5666946A (en) | 1994-07-13 | 1997-09-16 | Respirogenics Corporation | Apparatus for delivering drugs to the lungs |
FR2722765B1 (en) | 1994-07-25 | 1996-08-23 | Oreal | CONTAINER ALLOWING THE STORAGE OF AT LEAST TWO PRODUCTS, THE MIXTURE OF THESE PRODUCTS AND THE DISTRIBUTION OF THE MIXTURE THUS OBTAINED |
US5664706A (en) | 1994-10-13 | 1997-09-09 | Bespak Plc | Apparatus for dispensing liquid in aerosol spray form |
US5508269A (en) * | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
AU128844S (en) | 1994-10-21 | 1996-12-05 | Glaxo Wellcome Australia Ltd | Ampoule |
GB9421687D0 (en) | 1994-10-27 | 1994-12-14 | Aid Medic Ltd | Dosimetric spacer |
US5560837A (en) | 1994-11-08 | 1996-10-01 | Hewlett-Packard Company | Method of making ink-jet component |
US5707818A (en) * | 1994-12-13 | 1998-01-13 | Bsi Corporation | Device and method for simultaneously performing multiple competitive immunoassays |
US5582330A (en) | 1994-12-28 | 1996-12-10 | Allergan, Inc. | Specific volume dispenser |
US5588166A (en) | 1995-01-04 | 1996-12-31 | Burnett; John | Medical attachment device |
US5685491A (en) | 1995-01-11 | 1997-11-11 | Amtx, Inc. | Electroformed multilayer spray director and a process for the preparation thereof |
GB2298406B (en) | 1995-02-21 | 1998-05-06 | Bespak Plc | Dual component dispensing apparatus |
NO950760L (en) | 1995-02-28 | 1996-08-29 | Elkem Materials | Process for the preparation of alkyl halosilanes |
DK0730858T3 (en) * | 1995-03-09 | 1999-09-27 | Hansen Bernd | Plastic bottle and method for its manufacture |
DK0814860T3 (en) | 1995-03-14 | 2000-05-08 | Siemens Ag | Ultrasonic nebulizer with removable precision metering unit |
DK0814861T3 (en) | 1995-03-14 | 2002-10-07 | Siemens Ag | Interchangeable precision metering unit for ultrasonic atomizer |
US5503628A (en) | 1995-03-15 | 1996-04-02 | Jettek, Inc. | Patient-fillable hypodermic jet injector |
US5533497A (en) | 1995-03-27 | 1996-07-09 | Ryder; Steven L. | Sidestream aerosol generator and method in variable positions |
US6427682B1 (en) | 1995-04-05 | 2002-08-06 | Aerogen, Inc. | Methods and apparatus for aerosolizing a substance |
US6085740A (en) | 1996-02-21 | 2000-07-11 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US6782886B2 (en) | 1995-04-05 | 2004-08-31 | Aerogen, Inc. | Metering pumps for an aerosolizer |
US5586550A (en) | 1995-08-31 | 1996-12-24 | Fluid Propulsion Technologies, Inc. | Apparatus and methods for the delivery of therapeutic liquids to the respiratory system |
US6205999B1 (en) | 1995-04-05 | 2001-03-27 | Aerogen, Inc. | Methods and apparatus for storing chemical compounds in a portable inhaler |
US20020121274A1 (en) | 1995-04-05 | 2002-09-05 | Aerogen, Inc. | Laminated electroformed aperture plate |
US5758637A (en) | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US6014970A (en) * | 1998-06-11 | 2000-01-18 | Aerogen, Inc. | Methods and apparatus for storing chemical compounds in a portable inhaler |
US5474059A (en) | 1995-04-08 | 1995-12-12 | Cooper; Guy F. | Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient |
US5657926A (en) | 1995-04-13 | 1997-08-19 | Toda; Kohji | Ultrasonic atomizing device |
ES2142578T3 (en) * | 1995-05-02 | 2000-04-16 | Aloy Alexander Dr | DEVICE FOR THE SUPPLY OF A GAS FOR INHALATION. |
US5598836A (en) | 1995-05-26 | 1997-02-04 | Healthscan Products, Inc. | Metered dose inhalation unit with slide means |
JP3318578B2 (en) | 1995-05-26 | 2002-08-26 | サーモディックス,インコーポレイティド | Methods for promoting endothelialization and implantable products |
JP3320261B2 (en) | 1995-06-01 | 2002-09-03 | 株式会社ユニシアジェックス | Inhaler type dispenser |
US5609798A (en) * | 1995-06-07 | 1997-03-11 | Msp Corporation | High output PSL aerosol generator |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US5584285A (en) | 1995-06-07 | 1996-12-17 | Salter Labs | Breathing circuit apparatus for a nebulizer |
US5829723A (en) | 1995-06-28 | 1998-11-03 | Medex, Inc. | Medical device mounting structure |
WO2004096328A1 (en) | 1995-07-12 | 2004-11-11 | Hiroyuki Yokoi | Handy inhaler |
US5904773A (en) | 1995-08-11 | 1999-05-18 | Atotech Usa, Inc. | Fluid delivery apparatus |
US6000396A (en) | 1995-08-17 | 1999-12-14 | University Of Florida | Hybrid microprocessor controlled ventilator unit |
SE9502957D0 (en) | 1995-08-28 | 1995-08-28 | Pharmacia Ab | Device for displacing a member in a container |
US5797389A (en) | 1995-09-06 | 1998-08-25 | Ryder; Steven L. | Variable oxygen concentration high-flow nebulizer |
US5848587A (en) | 1995-09-21 | 1998-12-15 | Medi-Nuclear Corporation, Inc. | Aerosol medication delivery system |
US5617844A (en) | 1995-09-21 | 1997-04-08 | King; Russell W. | Aerosol medication delivery system |
US5639851A (en) * | 1995-10-02 | 1997-06-17 | Ethicon, Inc. | High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers |
JP3317827B2 (en) | 1995-10-09 | 2002-08-26 | 株式会社ユニシアジェックス | Dosing device |
US6254219B1 (en) | 1995-10-25 | 2001-07-03 | Hewlett-Packard Company | Inkjet printhead orifice plate having related orifices |
US6123413A (en) | 1995-10-25 | 2000-09-26 | Hewlett-Packard Company | Reduced spray inkjet printhead orifice |
US5714360A (en) * | 1995-11-03 | 1998-02-03 | Bsi Corporation | Photoactivatable water soluble cross-linking agents containing an onium group |
US5807335A (en) | 1995-12-22 | 1998-09-15 | Science Incorporated | Fluid delivery device with conformable ullage and fill assembly |
FR2743313B1 (en) | 1996-01-04 | 1998-02-06 | Imra Europe Sa | HIGH-YIELD SPRAYING DEVICE, ESPECIALLY MICRO-DROPLET WATER |
US5694920A (en) | 1996-01-25 | 1997-12-09 | Abrams; Andrew L. | Inhalation device |
US6026809A (en) * | 1996-01-25 | 2000-02-22 | Microdose Technologies, Inc. | Inhalation device |
US5823179A (en) | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
USD392184S (en) * | 1996-02-21 | 1998-03-17 | Automatic Liquid Packaging, Inc. | Vial with a frangible closure |
FR2746656B1 (en) * | 1996-03-26 | 1999-05-28 | System Assistance Medical | PRESSURE SENSOR NEBULIZER |
US5790151A (en) | 1996-03-27 | 1998-08-04 | Imaging Technology International Corp. | Ink jet printhead and method of making |
SE9601719D0 (en) * | 1996-05-06 | 1996-05-06 | Siemens Elema Ab | Dosage for supply of additive gas or liquid to respiratory gas in anesthesia or ventilator |
AUPN976496A0 (en) * | 1996-05-10 | 1996-05-30 | Glaxo Wellcome Australia Ltd | Unit dose dispensing device |
US5976344A (en) | 1996-05-10 | 1999-11-02 | Lucent Technologies Inc. | Composition for electroplating palladium alloys and electroplating process using that composition |
JP3418507B2 (en) | 1996-08-07 | 2003-06-23 | ワイケイケイ株式会社 | Piezoelectric vibration control method |
AUPO247496A0 (en) | 1996-09-23 | 1996-10-17 | Resmed Limited | Assisted ventilation to match patient respiratory need |
US5775506A (en) | 1996-09-25 | 1998-07-07 | Abbott Laboratories | Pharmaceutical ampul |
DE19647947A1 (en) | 1996-11-20 | 1998-05-28 | Pfeiffer Erich Gmbh & Co Kg | Discharge device for media |
AUPP855099A0 (en) * | 1999-02-09 | 1999-03-04 | Resmed Limited | Gas delivery connection assembly |
US5954268A (en) | 1997-03-03 | 1999-09-21 | Joshi; Ashok V. | Fluid delivery system |
US5948483A (en) | 1997-03-25 | 1999-09-07 | The Board Of Trustees Of The University Of Illinois | Method and apparatus for producing thin film and nanoparticle deposits |
DE19720701A1 (en) * | 1997-05-16 | 1998-11-19 | Gsf Forschungszentrum Umwelt | Device for applying a medicament aerosol via the lungs |
EP1009464A4 (en) * | 1997-05-16 | 2006-08-02 | Peter Craig Farrell | Nasal ventilation as a treatment for stroke |
US6055869A (en) | 1997-06-12 | 2000-05-02 | Stemme; Erik | Lift force fluid flow sensor for measuring fluid flow velocities |
US5839617A (en) | 1997-07-29 | 1998-11-24 | Owens-Illinois Closure Inc. | Pump dispenser |
US6045215A (en) | 1997-08-28 | 2000-04-04 | Hewlett-Packard Company | High durability ink cartridge printhead and method for making the same |
US6145963A (en) | 1997-08-29 | 2000-11-14 | Hewlett-Packard Company | Reduced size printhead for an inkjet printer |
US6044841A (en) | 1997-08-29 | 2000-04-04 | 1263152 Ontario Inc. | Breath actuated nebulizer with valve assembly having a relief piston |
US6139674A (en) | 1997-09-10 | 2000-10-31 | Xerox Corporation | Method of making an ink jet printhead filter by laser ablation |
JP3386050B2 (en) | 1997-10-06 | 2003-03-10 | オムロン株式会社 | Spraying equipment |
WO1999017754A1 (en) | 1997-10-08 | 1999-04-15 | Sepracor Inc. | Dosage form for aerosol administration |
US6216690B1 (en) * | 1997-10-15 | 2001-04-17 | Datex-Ohmeda, Inc. | Method and apparatus for rapid control of set inspired gas concentration in anesthesia delivery systems |
US6155676A (en) | 1997-10-16 | 2000-12-05 | Hewlett-Packard Company | High-durability rhodium-containing ink cartridge printhead and method for making the same |
US6037587A (en) * | 1997-10-17 | 2000-03-14 | Hewlett-Packard Company | Chemical ionization source for mass spectrometry |
US6039696A (en) * | 1997-10-31 | 2000-03-21 | Medcare Medical Group, Inc. | Method and apparatus for sensing humidity in a patient with an artificial airway |
AUPP026997A0 (en) | 1997-11-07 | 1997-12-04 | Resmed Limited | Administration of cpap treatment pressure in presence of apnea |
DE1149602T1 (en) * | 1997-11-19 | 2002-04-04 | Microflow Eng Sa | Spray device for an inhaler suitable for respiratory therapy |
US6096011A (en) | 1998-01-29 | 2000-08-01 | Medrad, Inc. | Aseptic connector and fluid delivery system using such an aseptic connector |
US6358058B1 (en) * | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
US6223746B1 (en) | 1998-02-12 | 2001-05-01 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler pump |
US6158431A (en) | 1998-02-13 | 2000-12-12 | Tsi Incorporated | Portable systems and methods for delivery of therapeutic material to the pulmonary system |
US6026807A (en) * | 1998-02-27 | 2000-02-22 | Diemolding Corporation | Metered dose inhaler cloud chamber |
US6204182B1 (en) | 1998-03-02 | 2001-03-20 | Hewlett-Packard Company | In-situ fluid jet orifice |
EP1059953B1 (en) | 1998-03-05 | 2005-09-07 | Zivena, Inc. | Pulmonary dosing system |
GB9808182D0 (en) | 1998-04-17 | 1998-06-17 | The Technology Partnership Plc | Liquid projection apparatus |
US6578571B1 (en) | 1998-04-20 | 2003-06-17 | Infamed Ltd. | Drug delivery device and methods therefor |
US6082358A (en) | 1998-05-05 | 2000-07-04 | 1263152 Ontario Inc. | Indicating device for aerosol container |
US6336453B1 (en) | 1999-04-30 | 2002-01-08 | Trudell Medical International | Indicating device for aerosol container |
US6068148A (en) | 1998-05-26 | 2000-05-30 | Automatic Liquid Packaging, Inc. | Hermetically sealed container including a nozzle with a sealing bead |
US20020104530A1 (en) | 1998-06-11 | 2002-08-08 | Aerogen, Inc. | Piezoelectric polymer flow sensor and methods |
US6152130A (en) | 1998-06-12 | 2000-11-28 | Microdose Technologies, Inc. | Inhalation device with acoustic control |
US6142146A (en) | 1998-06-12 | 2000-11-07 | Microdose Technologies, Inc. | Inhalation device |
US6260549B1 (en) | 1998-06-18 | 2001-07-17 | Clavius Devices, Inc. | Breath-activated metered-dose inhaler |
US6106504A (en) | 1998-07-15 | 2000-08-22 | Urrutia; Hector | Drip chamber for medical fluid delivery system |
US6182662B1 (en) * | 1998-07-23 | 2001-02-06 | Mcghee Chad J. | Intravenous transport/support device |
AUPP496198A0 (en) * | 1998-07-31 | 1998-08-20 | Resmed Limited | Switches with graphical display |
GB2343122B (en) | 1998-10-26 | 2003-01-08 | Medic Aid Ltd | Improvements in and relating to nebulisers |
AUPP693398A0 (en) | 1998-11-05 | 1998-12-03 | Resmed Limited | Fault diagnosis in CPAP and NIPPV devices |
WO2000027455A1 (en) | 1998-11-06 | 2000-05-18 | Salter Labs | Nebulizer mouthpiece and accessories |
DK1005917T3 (en) | 1998-12-01 | 2007-03-05 | Microflow Eng Sa | Inhaler with ultrasonic wave atomizer with nozzle openings positioned corresponding to the tips of a pattern of standing waves |
HUP0105226A3 (en) * | 1998-12-17 | 2003-03-28 | Pathogenesis Corp Seattle | Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic |
JP3312216B2 (en) | 1998-12-18 | 2002-08-05 | オムロン株式会社 | Spraying equipment |
US6163588A (en) | 1998-12-23 | 2000-12-19 | General Electric Company | Core plate and reactor internal pump differential pressure lines for a boiling water reactor |
US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
US6216025B1 (en) | 1999-02-02 | 2001-04-10 | Optosonics, Inc. | Thermoacoustic computed tomography scanner |
US6390091B1 (en) * | 1999-02-03 | 2002-05-21 | University Of Florida | Method and apparatus for controlling a medical ventilator |
US6196218B1 (en) | 1999-02-24 | 2001-03-06 | Ponwell Enterprises Ltd | Piezo inhaler |
US6328030B1 (en) | 1999-03-12 | 2001-12-11 | Daniel E. Kidwell | Nebulizer for ventilation system |
AUPQ019899A0 (en) * | 1999-05-06 | 1999-06-03 | Resmed Limited | Control of supplied pressure in assisted ventilation |
US6328033B1 (en) | 1999-06-04 | 2001-12-11 | Zohar Avrahami | Powder inhaler |
US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
SE9902627D0 (en) | 1999-07-08 | 1999-07-08 | Siemens Elema Ab | Medical nebulizer |
US6235177B1 (en) | 1999-09-09 | 2001-05-22 | Aerogen, Inc. | Method for the construction of an aperture plate for dispensing liquid droplets |
US6530370B1 (en) * | 1999-09-16 | 2003-03-11 | Instrumentation Corp. | Nebulizer apparatus |
US6216916B1 (en) | 1999-09-16 | 2001-04-17 | Joseph S. Kanfer | Compact fluid pump |
JP3673893B2 (en) | 1999-10-15 | 2005-07-20 | 日本碍子株式会社 | Droplet discharge device |
SE9904382D0 (en) | 1999-12-02 | 1999-12-02 | Siemens Elema Ab | High Frequency Oscillation Patient Fan System |
US6412481B1 (en) | 1999-12-23 | 2002-07-02 | Robert Bienvenu | Sealed backpressure attachment device for nebulizer |
DE19962280A1 (en) | 1999-12-23 | 2001-07-12 | Draeger Medizintech Gmbh | Ultrasonic evaporator for liquids has exciter circuit to operate transducer at optimum vibration range |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
WO2001058514A1 (en) | 2000-02-11 | 2001-08-16 | Profile Respiratory Systems Limited | Drug delivery apparatus |
US6516798B1 (en) | 2000-03-07 | 2003-02-11 | Timothy A. Davies | Method of breathing tracheally |
US6539937B1 (en) | 2000-04-12 | 2003-04-01 | Instrumentarium Corp. | Method of maximizing the mechanical displacement of a piezoelectric nebulizer apparatus |
US7971588B2 (en) | 2000-05-05 | 2011-07-05 | Novartis Ag | Methods and systems for operating an aerosol generator |
US7600511B2 (en) | 2001-11-01 | 2009-10-13 | Novartis Pharma Ag | Apparatus and methods for delivery of medicament to a respiratory system |
US7100600B2 (en) | 2001-03-20 | 2006-09-05 | Aerogen, Inc. | Fluid filled ampoules and methods for their use in aerosolizers |
MXPA02010884A (en) * | 2000-05-05 | 2003-03-27 | Aerogen Ireland Ltd | Apparatus and methods for the delivery of medicaments to the respiratory system. |
US6948491B2 (en) | 2001-03-20 | 2005-09-27 | Aerogen, Inc. | Convertible fluid feed system with comformable reservoir and methods |
US6341732B1 (en) * | 2000-06-19 | 2002-01-29 | S. C. Johnson & Son, Inc. | Method and apparatus for maintaining control of liquid flow in a vibratory atomizing device |
US6543443B1 (en) | 2000-07-12 | 2003-04-08 | Aerogen, Inc. | Methods and devices for nebulizing fluids |
US6769626B1 (en) | 2000-10-30 | 2004-08-03 | Instrumentarium Corp. | Device and method for detecting and controlling liquid supply to an apparatus discharging liquids |
US6601581B1 (en) | 2000-11-01 | 2003-08-05 | Advanced Medical Applications, Inc. | Method and device for ultrasound drug delivery |
US6581595B1 (en) | 2000-11-14 | 2003-06-24 | Sensormedics Corporation | Positive airway pressure device with indirect calorimetry system |
SE0004701D0 (en) | 2000-12-19 | 2000-12-19 | Siemens Elema Ab | Anesthetic vaporizers |
US20020078958A1 (en) | 2000-12-21 | 2002-06-27 | Sensormedics Corporation | Infant CPAP system with airway pressure control |
US6546927B2 (en) | 2001-03-13 | 2003-04-15 | Aerogen, Inc. | Methods and apparatus for controlling piezoelectric vibration |
US6550472B2 (en) | 2001-03-16 | 2003-04-22 | Aerogen, Inc. | Devices and methods for nebulizing fluids using flow directors |
US6732944B2 (en) | 2001-05-02 | 2004-05-11 | Aerogen, Inc. | Base isolated nebulizing device and methods |
US6554201B2 (en) | 2001-05-02 | 2003-04-29 | Aerogen, Inc. | Insert molded aerosol generator and methods |
US20020162551A1 (en) | 2001-05-02 | 2002-11-07 | Litherland Craig M. | Cymbal-shaped actuator for a nebulizing element |
US6725858B2 (en) | 2001-05-07 | 2004-04-27 | Hudson Respiratory Care Inc. | Valved aerosol tee adapter assembly |
DE60225273T2 (en) | 2001-05-18 | 2009-03-19 | Smaldone, Gerald C. | Face masks for pressure-applied drug delivery systems |
US6964761B1 (en) | 2001-12-12 | 2005-11-15 | New York University | Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-γ |
WO2003057291A1 (en) | 2002-01-07 | 2003-07-17 | Aerogen, Inc. | Devices and methods for nebulizing fluids for inhalation |
US6851626B2 (en) * | 2002-01-07 | 2005-02-08 | Aerogen, Inc. | Methods and devices for nebulizing fluids |
US6745770B2 (en) | 2002-01-08 | 2004-06-08 | Resmed Limited | Flow diverter for controlling the pressure and flow rate in a CPAP device |
EP1474196B1 (en) | 2002-01-15 | 2016-08-17 | Novartis AG | Methods and systems for operating an aerosol generator |
US6845770B2 (en) * | 2002-01-15 | 2005-01-25 | Aerogen, Inc. | Systems and methods for clearing aerosols from the effective anatomic dead space |
US6860268B2 (en) * | 2002-02-06 | 2005-03-01 | Shelly Bohn | Pediatric ventilation mask and headgear system |
US7334580B2 (en) * | 2002-05-07 | 2008-02-26 | Smaldone Gerald C | Methods, devices and formulations for targeted endobronchial therapy |
US7607436B2 (en) | 2002-05-06 | 2009-10-27 | The Research Foundation Of State University Of New York | Methods, devices and formulations for targeted endobronchial therapy |
AU2003256253A1 (en) * | 2002-05-20 | 2003-12-02 | Aerogen, Inc. | Aerosol for medical treatment and methods |
DE10238683A1 (en) * | 2002-08-19 | 2004-03-11 | Rist, Max, Dr. | Device for influencing gas flows |
US7347203B2 (en) | 2002-09-16 | 2008-03-25 | Thayer Medical Corporation | Heat and moisture filter exchanger and method |
US7849853B2 (en) * | 2003-02-11 | 2010-12-14 | Trudell Medical International | Ventilator circuit and the method for the use thereof |
NZ626589A (en) | 2003-02-21 | 2016-01-29 | Resmed Ltd | Nasal assembly |
JP4466991B2 (en) | 2003-05-22 | 2010-05-26 | 英明 森山 | Crystal growth apparatus and method |
US8616195B2 (en) * | 2003-07-18 | 2013-12-31 | Novartis Ag | Nebuliser for the production of aerosolized medication |
US7082947B2 (en) | 2003-10-29 | 2006-08-01 | Smaldone Gerald C | Face mask for use in pressurized drug delivery systems |
US8375947B2 (en) | 2003-11-17 | 2013-02-19 | Novartis Ag | Introducing aerosol into a ventilator |
US7946291B2 (en) | 2004-04-20 | 2011-05-24 | Novartis Ag | Ventilation systems and methods employing aerosol generators |
US7290541B2 (en) | 2004-04-20 | 2007-11-06 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
-
2005
- 2005-03-24 US US11/090,328 patent/US7971588B2/en active Active
-
2006
- 2006-03-22 BR BRPI0609725A patent/BRPI0609725B8/en active IP Right Grant
- 2006-03-22 KR KR1020077021946A patent/KR101301163B1/en active IP Right Grant
- 2006-03-22 CN CN2006800092967A patent/CN101146517B/en active Active
- 2006-03-22 MX MX2007011786A patent/MX2007011786A/en active IP Right Grant
- 2006-03-22 ES ES06739177.1T patent/ES2642041T3/en active Active
- 2006-03-22 WO PCT/US2006/010278 patent/WO2006102345A2/en active Application Filing
- 2006-03-22 JP JP2008503098A patent/JP5008093B2/en active Active
- 2006-03-22 NZ NZ595112A patent/NZ595112A/en not_active IP Right Cessation
- 2006-03-22 EP EP06739177.1A patent/EP1868570B1/en active Active
- 2006-03-22 AU AU2006227168A patent/AU2006227168B2/en active Active
- 2006-03-22 CA CA2599018A patent/CA2599018C/en active Active
- 2006-03-22 NZ NZ561943A patent/NZ561943A/en unknown
-
2007
- 2007-09-23 IL IL186162A patent/IL186162A/en active IP Right Grant
-
2008
- 2008-01-23 US US12/018,716 patent/US8196573B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NZ595112A (en) | 2013-03-28 |
BRPI0609725A2 (en) | 2010-04-20 |
IL186162A (en) | 2016-05-31 |
US7971588B2 (en) | 2011-07-05 |
CN101146517A (en) | 2008-03-19 |
IL186162A0 (en) | 2008-01-20 |
AU2006227168A2 (en) | 2006-09-28 |
JP2008536546A (en) | 2008-09-11 |
US20050217666A1 (en) | 2005-10-06 |
MX2007011786A (en) | 2007-11-07 |
CA2599018A1 (en) | 2006-09-28 |
EP1868570B1 (en) | 2017-09-20 |
JP5008093B2 (en) | 2012-08-22 |
BRPI0609725B8 (en) | 2021-05-25 |
CN101146517B (en) | 2013-09-04 |
US20080142002A1 (en) | 2008-06-19 |
WO2006102345A3 (en) | 2007-01-25 |
AU2006227168A1 (en) | 2006-09-28 |
WO2006102345A2 (en) | 2006-09-28 |
ES2642041T3 (en) | 2017-11-15 |
US8196573B2 (en) | 2012-06-12 |
BRPI0609725B1 (en) | 2020-06-16 |
EP1868570A2 (en) | 2007-12-26 |
AU2006227168B2 (en) | 2012-04-26 |
KR20070113257A (en) | 2007-11-28 |
KR101301163B1 (en) | 2013-09-03 |
NZ561943A (en) | 2010-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2599018C (en) | Methods and systems for operating an aerosol generator | |
US8336545B2 (en) | Methods and systems for operating an aerosol generator | |
JP7463474B2 (en) | Aerosol delivery systems and methods | |
US7267121B2 (en) | Aerosol delivery apparatus and method for pressure-assisted breathing systems | |
US7946291B2 (en) | Ventilation systems and methods employing aerosol generators | |
US6076519A (en) | Passive inspiratory nebulizer system | |
RU2661142C2 (en) | System with apparatus for artificial ventilation of lungs, intended for aerosol supply | |
US20100282247A1 (en) | Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin | |
US20080017198A1 (en) | Aerosol delivery apparatus and method for pressure-assisted breathing systems | |
US20170368275A1 (en) | Nebulizer for infants and respiratory compromised patients | |
AU2012258488A1 (en) | Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin | |
CN219090641U (en) | Atomizer capable of self-adaptively discharging fog | |
WO2018127591A1 (en) | Jet aerosol dispenser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |